<allTrials totalCount="40" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-26T00:00:00.000Z">63412511</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of a three-month course of rosuvastatin in patients with Systemic Lupus Erythematosus</title>
      <scientificTitle/>
      <acronym>Rosuvastatin in SLE</acronym>
      <studyHypothesis>Systemic lupus erythematosus (SLE) is a rheumatologic multi-systemic auto-immune disease particularly affecting joints, skin and kidneys. The aim of this trial was to investigate the effects of rosuvastatin on markers of lipid metabolism and inflammatory parameters in patients with SLE.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Measured at baseline and after three months of treatment:
1. Total cholesterol 
2. Low density lipoprotein (LDL) cholesterol
3. C-reactive protein (CRP)
4. Tumour necrotising factor (TNF)</primaryOutcome>
      <secondaryOutcome>Measured at baseline and after three months of treatment:
1. Interleukin-6 (IL6), interleukin-10 (IL10), interleukin-8 (IL8)
2. Complement C3 and C4q
3. Anti-double stranded deoxyribonucleic acid (anti-dsDNA)
4. Urine protein</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Committee of the Slotervaart Hospital (The Netherlands) on the 29th November 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63412511</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, open-labelled, cross-over study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d60ff033-707e-4bb9-a5f6-3d5f440df5ec">
	  <name>Department of Internal Medicine</name>
	  <address/>
	  <city>Maastricht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6229 HX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with chronic, non-acute SLE
2. Greater than 18 years old, either sex</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>19</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>19</totalTarget>
      <exclusion>1. Use of statins
2. Pregnancy
3. Raised liver enzymes
4. Recent (less than three months) major surgery or myocardial infarction</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systemic lupus erythematosus</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Systemic lupus erythematosus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Rosuvastatin 10 mg once daily.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosuvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17593-0</funderId>
      <contactId>Contact55560_17593</contactId>
      <sponsorId>Sponsor54139</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55560_17593">
    <title>Prof</title>
    <forename>Hugo</forename>
    <surname>ten Cate</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Internal Medicine
Academisch Ziekenhuis Maastricht</address>
      <city>Maastricht</city>
      <country>Netherlands</country>
      <zip>6229 HX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">H.Tencate@BIOCH.unimaas.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54139">
    <organisation>AstraZeneca (The Netherlands)</organisation>
    <website>http://www.astrazeneca.nl</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Postbus 599</address>
      <city>Zoetermeer</city>
      <country>Netherlands</country>
      <zip>2700 AN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)79 363 2222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info.nl@astrazeneca.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476086.b</gridId>
    <rorId>https://ror.org/021tmn508</rorId>
  </sponsor>
  <funder id="Funder17593-0">
    <name>AstraZeneca (The Netherlands) - unrestricted research grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-03-26T00:00:00.000Z">52111135</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of three diagnostic tools for latent tuberculosis in haemodialysis patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Latent tuberculosis is hard to diagnose in immunocompromised hosts like haemodialysis patients, and widespread bacille calmette-guerin (BCG) vaccination make it complicated to interpretate Mantoux test results in Korea. Therefore, we need more sensitive and specific diagnostic tools for latent tuberculosis in haemodialysis patients. 

Hypothesis:
T-spot assay or Quantiferon assay is more sensitive and specific than Mantoux test for latent tuberculosis in haemodialysis patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Skin test: positive or negative
2. Quantiferon-gold: positive or negative
3. T-spot test: positive or negative

These outcomes will be measured on the day of testing.</primaryOutcome>
      <secondaryOutcome>1. Skin test: size of induration
2. Quantiferon-gold: concentration
3. T-spot test: number, mean area

These outcomes will be measured on the day of testing.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board (IRB) of Gachon University of Medicine and Science on the 28th February 2008 (ref: 20080228 tuberculosis in haemodialysis).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52111135</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, observational, cross-sectional, open trial</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cross-section survey</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f7590e94-2e99-4147-96a9-86319001fdd7">
	  <name>Division of Nephrology</name>
	  <address/>
	  <city>Incheon</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>405-760</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chronic maintenance haemodialysis patients who continue to receive haemodialysis for more than three months in the Gil Medical Centre
2. Older than 18 years, and less than 80 years, either sex
3. Agrees to participate in this trial
4. Medical staff in the haemodialysis centre of the Gil Medical Centre</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="80.0"/>
      <gender>Both</gender>
      <targetEnrolment>162</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>162</totalTarget>
      <exclusion>1. Patients who suffer from skin diseases which may interfere with Mantoux test
2. Patients with an active infection, except tuberculosis
3. Patients who cannot make independent decision due to mental disorders</exclusion>
      <patientInfoSheet>Not available in web format, please contact Jaeseok Yang at jcyjs@hanafos.com to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Latent tuberculosis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Agreement of three diagnostic tests for latent tuberculosis will be tested in haemodialysis patients. Blood samples are taken for:
1. Quantiferon-gold assay, an enzyme linked immunosorbent assay (ELISA) assay for interferon gamma in response to tuberculosis specific antigens
2. T-spot assay, an enzyme-linked immunosorbent spot (ELISPOT) assay for interferon gamma

After sampling, the Mantoux test will be performed, and the results will be read in two days. Agreement of three test results will be analysed using kappa coefficients, and results will be analysed per each categories of risk groups such as low risk group, casual contact group, latent tuberculosis patients, and active tuberculosis patients. Agreement will be also analysed in medical staff group with normal immunity.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17617-0</funderId>
      <contactId>Contact55587_17617</contactId>
      <sponsorId>Sponsor54163</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55587_17617">
    <title>Prof</title>
    <forename>Jaeseok</forename>
    <surname>Yang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Nephrology
Department of Internal Medicine
Gil Medical Center
1198 Guwol-dong
Namdong-gu</address>
      <city>Incheon</city>
      <country>Korea, South</country>
      <zip>405-760</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54163">
    <organisation>Gachon University of Medicine and Science (South Korea)</organisation>
    <website>http://home.gachon.ac.kr/icc/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Institutional Review Board (IRB)
Department of Pharmacy
Gil Medical Centre
1198 Guwol-dong
Namdong-gu</address>
      <city>Incheon</city>
      <country>Korea, South</country>
      <zip>405-760</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.256155.0</gridId>
    <rorId>https://ror.org/03ryywt80</rorId>
  </sponsor>
  <funder id="Funder17617-0">
    <name>Gachon University of Medicine and Science (South Korea) - Division of Nephrology, Department of Internal Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">11431649</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>25- versus 29-gauge Quincke spinal needles</title>
      <scientificTitle>Comparison of 25- versus 29-gauge Quincke spinal needles for minor anorectal surgery as well as abdominal caesarean section in respect of patient satisfaction and handling</scientificTitle>
      <acronym/>
      <studyHypothesis>It is considered, that the incidence of post-puncture dural headache is correlated with the size of the spinal needle. For reason of patients' satisfaction and to minimize complications, a 29-gauge spinal needle is suitable for this purpose, especially in pregnant patients and patients undergoing ambulatory surgery. Though, the handling of this very thin spinal needle is described as difficult and therefore denied by several anaesthesiologists. 

The aim of this study is to evaluate the patients' satisfaction, the incidence of post-puncture dural headache and the handling conditions for the anaesthesiologist. 

Hypothesis:
The performance of a spinal anaesthesia with 29-gauge compared to a 25-gauge Quincke needles has a lower incidence of complications in patients undergoing minor anorectal surgery and abdominal caesarean section.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of post-dural puncture headache and other complications, measured one week after anaesthesia.</primaryOutcome>
      <secondaryOutcome>Time for the performance of spinal anaesthesia and occurring complications, measured one week after anaesthesia.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medizinische Ethik-Kommission II: Medizinische Fakultat Mannheim der Ruprecht-Karls-Universitat Heidelberg) on the 19th September 2007 (ref: 2007-236N-MA).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11431649</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>anaesMA2007-03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="75eefce8-88ad-4c92-8d6b-08065f2f0f55">
	  <name>University Clinic Mannheim</name>
	  <address/>
	  <city>Mannheim</city>
	  <state/>
	  <country>Germany</country>
	  <zip>68167</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients (male/female) with minor anorectal surgery, or 
2. Patients (female) for abdominal caesarean section
3. Age 18 - 80 years
4. American Society of Anaesthesiology (ASA) grade I - III
5. No contraindications for spinal anaesthesia</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>1. Contraindications for spinal anaesthesia
2. Allergy against local anaesthetics</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-puncture dural headache</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Post-puncture dural headache</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients are 1:1 randomised to either a 25-gauge or a 29-gauge spinal needle. Patients receive a questionnaire to obtain information about satisfaction and occurring complications. The time for the performance of the spinal anaesthesia and problems with the handling of the spinal needle are recorded by the anaesthesiologist.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17347-0</funderId>
      <contactId>Contact55308_17347</contactId>
      <sponsorId>Sponsor53876</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55308_17347">
    <title>Prof</title>
    <forename>Grietje</forename>
    <surname>Beck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Clinic Mannheim
Department of Anaesthesiology and Critical Care Medicine
Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">grietje.beck@anaes.ma.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53876">
    <organisation>B. Braun Melsungen AG (Germany)</organisation>
    <website>http://www.bbraun.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Carl-Braun-Strasse 1</address>
      <city>Melsungen</city>
      <country>Germany</country>
      <zip>34212</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@bbraun.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.462046.2</gridId>
    <rorId>https://ror.org/04nxj7050</rorId>
  </sponsor>
  <funder id="Funder17347-0">
    <name>B. Braun Melsungen AG (Germany) - provided the spinal needles</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">36101176</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Hospital at home care in chronic obstructive pulmonary disease (COPD): a study on the associated health economy and disease-related quality of life</title>
      <scientificTitle>Hospital at home care in exacerbations of chronic obstructive pulmonary disease (COPD)</scientificTitle>
      <acronym>HBKOLS</acronym>
      <studyHypothesis>Previous studies in other countries indicate that home treatment with nursing support is suitable in selected patients with exacerbations of chronic obstructive pulmonary disease (COPD), presenting to hospital as an emergency. 

Hypothesis: 
Three days of hospital at home care in mild to moderate exacerbations of COPD is cost saving in the Norwegian health care system and implies at least the same level of disease-related quality of life as traditional hospital care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Health economy measures.

Time points: 6 weeks, 6 months and 12 months.</primaryOutcome>
      <secondaryOutcome>1. Level of disease-related quality of life, measured with the St. George Respiratory Questionnaire
2. Mental health (level of anxiety and depression), measured with the Hospital Anxiety and Depression Scale

Time points: 6 weeks, 6 months and 12 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Regional Ethics Committee for Medical Research of East Norway on the 21st December 2007 (ref: 1.2007.2613).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36101176</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b38f729-f8b1-4940-9305-8d9f5c94fc4e">
	  <name>HØKH</name>
	  <address/>
	  <city>Lørenskog</city>
	  <state/>
	  <country>Norway</country>
	  <zip>1478</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients under 80 years of age, either sex, with exacerbation of COPD
2. Presenting to the hospital as an emergency</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Serious exacerbation including impending or actual respiratory failure
2. Serious comorbidity</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Hospital-at-home group (experimental arm): 
Three days organised by the hospitals with specially trained nurses. In the same period of time the patient can contact the lung department at the hospital by phone for advice. Thereafter, if medical follow up is needed, by the primary care system (primary physician, home nurses).

Hospital group (control arm): 
As long as needed in the hospital. Thereafter, if needed, by the primary care personnel as for the other group. In contrast to the other group, the length of the in-hospital treatment is not specified. 

Follow up for both groups: After 6 weeks, 6 months and 12 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17434-0</funderId>
      <funderId>Funder17434-1</funderId>
      <contactId>Contact55395_17434</contactId>
      <sponsorId>Sponsor53965</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55395_17434">
    <title>Dr</title>
    <forename>Torbjørn </forename>
    <surname>Haugen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>HØKH
Akershus Unversitetssykehus HF
Sykehusveien 27</address>
      <city>Lørenskog</city>
      <country>Norway</country>
      <zip>1478</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53965">
    <organisation>Regional Authorities for Hospital Care, South-East Norway (Helse Sør-Øst Norge RHF) (Norway)</organisation>
    <website>http://www.helse-ost.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>PO Box 404</address>
      <city>Hamar</city>
      <country>Norway</country>
      <zip>2301</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+47 625 85 500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">postmottak@helse-ost.no</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.454198.5</gridId>
    <rorId>https://ror.org/02qx2s478</rorId>
  </sponsor>
  <funder id="Funder17434-0">
    <name>Regional Authorities for Hospital Care, South-Eastern Norway (Helse Sør-Øst RHF) (Norway)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17434-1">
    <name>The Norwegian Research Council (Norsk Forskningsråd) (Norway)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">75453816</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dietary fibre supplementation to prevent ulcerative colitis relapse: randomised double-blind placebo controlled clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>By taking 60 g of oat bran daily the relapse rate of patients with ulcerative colitis will be lowered from 40% to 20% at six months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Colitis relapse at six months.</primaryOutcome>
      <secondaryOutcome>The following will be assessed at six months:
1. General health
2. Bowel symptoms 
3. Faecal butyrate concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ethics committee of Linköping University, Sweden (ref: M 159-04)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75453816</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>v.13</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-07-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fa33c085-ab64-4b75-9d53-b0161ff16756">
	  <name>Norrköping Hospital NSÖ stab</name>
	  <address/>
	  <city>Norrköping</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>S-60182</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults with ulcerative colitis or proctitis in clinical and endoscopic remisson following a colitis relapse within prior 12 months
2. Written consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>130</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>130</totalTarget>
      <exclusion>1. Antibiotics at inclusion
2. Steroids in last two weeks
3. Ongoing treatment with immunosuppressive drugs
4. Pregnancy or planned pregnancy
5. Concomitant serious disorder
6. Inability to comply with study protocol</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (only in Swedish)</patientInfoSheet>
      <recruitmentStart>2006-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-07-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ulcerative colitis and proctitis in remission</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Ulcerative colitis and proctitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>60 g of oat bran to the daily diet for six months versus no intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Oat bran</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17486-0</funderId>
      <funderId>Funder17486-1</funderId>
      <contactId>Contact55448_17486</contactId>
      <sponsorId>Sponsor54028</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55448_17486">
    <title>Prof</title>
    <forename>Claes</forename>
    <surname>Hallert</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norrköping Hospital NSÖ stab</address>
      <city>Norrköping</city>
      <country>Sweden</country>
      <zip>S-60182 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)70 543 8282 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claes.Hallert@telia.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54028">
    <organisation>Lantmännen Food (Sweden)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Ingmar Börjesson
R&amp;D Department</address>
      <city>Järna</city>
      <country>Sweden</country>
      <zip>153 81</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 519 787 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ingmar.borjesson@lantmannen.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.502516.5</gridId>
  </sponsor>
  <funder id="Funder17486-0">
    <name>Lantmannen Food R&amp;D (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17486-1">
    <name>Medical Research Council of South-East Sweden (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">19821978</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Met-Hb and inflammation markers with tumescence local anaesthesia (TLA)</title>
      <scientificTitle>Met-Hb-concentration and inflammation markers in patients undergoing tumescence local anaesthesia (TLA) with supramaximal dosages of prilocaine</scientificTitle>
      <acronym/>
      <studyHypothesis>Tumescence local anaesthesia (TLA) is an established anaesthesia technique, where large amounts of highly diluted local anaesthetics are used. Due to its low toxicity, prilocaine is used frequently. Though, prilocaine can - dosage-dependant - cause a methemoglobinaemia, leading to a reduced oxygen transport capacity. Furthermore, certain processes of the inflammation cascade are initiated. These effects are important for ambulatory patients and the following healing process. 

The aim of the study is to evaluate the Met-Hb concentration and inflammation markers like  interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8), tumour necrotising factor (TNF), C-reactive protein (CRP) in a chronological sequence.

Hypothesis:
TLA in supramaximal dosages of prilocaine has an influence on plasmatic inflammation markers, which will elevate in the first 48 hours. Furthermore, the Met-Hb production will not be finished within this time.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Met-Hb-concentration over the time, measured over 48 hours.</primaryOutcome>
      <secondaryOutcome>Elevation of inflammation markers, measured over 48 hours.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medizinische Ethik-Komission II: Medizinische Fakultat Mannheim der Ruprechts-Karls-Universitat Heidelberg) on the 22nd November 2007 (ref: 2007-258N-MA)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19821978</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>anaesMA2007-02</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational study until 48 hours after surgery</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="adaa9697-0634-437a-ad35-cd5ebac75cc4">
	  <name>University Clinic Mannheim</name>
	  <address/>
	  <city>Mannheim</city>
	  <state/>
	  <country>Germany</country>
	  <zip>68167</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients (male/female) with operations which are performed in TLA with prilocaine
2. Age: 18 - 85 years
3. American Society of Anaesthesiologists (ASA) grade I - III
4. No allergy against prilocaine</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Allergy against prilocaine
2. Pregnancy
3. Patient denies operation in TLA</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tumescence local anaesthesia (TLA)/established anaesthesia techniques</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Anaesthesia techniques</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>As a standard procedure in our clinic, patients with dermatological operations will receive a TLA with more than 600 mg prilocaine. Seven blood samples (approximately 8 ml) will be taken 0, 1, 2, 4, 12, 24 and 48 hours after TLA, where the following parameters will be determined from:   
1. Demographic data and vital parameters
2. Met-Hb-concentration
3. Prilocaine-concentration
4. IL-1
5. IL-6
6. IL-8
7. TNF-alpha
8. CRP
9. Procalcitonin (PCT)
10. Creatine kinase (CK)
11. Lactate dehydrogenase (LDH)
12. Reticulocytes
13. Myoglobin
14. Haptoglobin 
15. Complications</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prilocaine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17346-0</funderId>
      <contactId>Contact55307_17346</contactId>
      <sponsorId>Sponsor53875</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55307_17346">
    <title>Prof</title>
    <forename>Grietje</forename>
    <surname>Beck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Clinic Mannheim
Department of Anaesthesiology and Critical Care Medicine
Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">grietje.beck@anaes.ma.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53875">
    <organisation>University Clinic Mannheim (Germany) - Department of Anaesthesiology and Critical Care Medicine </organisation>
    <website>http://www.klinikum-mannheim.de/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marc.schmittner@anaes.ma.uni.heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411778.c</gridId>
    <rorId>https://ror.org/05sxbyd35</rorId>
  </sponsor>
  <funder id="Funder17346-0">
    <name>University Clinic Mannheim (Germany) - Department of Anaesthesiology and Critical Care Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-13T00:00:00.000Z">01121161</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of lifespan in AN69ST with two different heparinization strategies</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Reduction of heparin dose in acute renal failure treated with hemodiafiltration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Filter lifespan, defined as the time period between patient's connection and filter disconnection due to filter clotting.</primaryOutcome>
      <secondaryOutcome>Adverse events, monitored for up to 24 days of treatment</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Local research ethics committee, Göteborg, Sweden. Date of approval: 17/12/2007 (Dnr. 576-07)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01121161</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1446</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Monocentric, open, randomised and controlled study with two parallel groups.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ae69dc32-626c-4977-adfb-92a93462aa2d">
	  <name>Sahlgrenska University Hospital</name>
	  <address/>
	  <city>Gothenburg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE- 413 45</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients requiring continuous renal replacement therapies (CRRT) 
2. Aged 18 and over 
3. Patients weighing 30-120 kg 
4. Patients having signed a written consent to participate in the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44</totalTarget>
      <exclusion>1. History of heparin antibodies or heparin-induces thrombocytopenia
2. Known hypertensive to any dialysis membrane
3. Current enrolment in another trial which could impact the successful completion of this study
4. Patients under guardianship
5. Patient anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week .These patients  can eventually be included in a later more stable phase
6. Unconscious patients for whom no relative or person of trust can give consent to treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study
7. Patient requiring anticoagulation for other indications e.g., valvular surgery or extracorporeal ventricular assist devices
8. Patients with active bleeding who does not require heparinization</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (in Swedish only)</patientInfoSheet>
      <recruitmentStart>2008-02-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute renal failure/  fluid overload</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Acute renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The same dialysis membrane, AN69ST, will be used for both the intervention and control treatment. Two different heparinization strategies will be compared: 

Control group (usual heparin doses): Bolus at start (between 1,000 IU - 2,500 IU) + usual infusion dose (10 IU/kg/h)  
Intervention group (Reduction of heparin dose): No bolus at start + infusion decreased by 50% (5 IU/kg/h)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17516-0</funderId>
      <contactId>Contact55478_17516</contactId>
      <sponsorId>Sponsor54061</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55478_17516">
    <title>Dr</title>
    <forename>Beng-Åke</forename>
    <surname>Henriksson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sahlgrenska University Hospital 
Department of Intensive Care (CIVA) </address>
      <city>Gothenburg</city>
      <country>Sweden</country>
      <zip>SE- 413 45</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54061">
    <organisation>Gambro Lundia AB (Sweden)</organisation>
    <website>http://www.gambro.com/int</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Clinical Trial Function
Clinical Affairs
P.O. Box 10101</address>
      <city>Lund</city>
      <country>Sweden</country>
      <zip>SE -220 10</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.420188.7</gridId>
    <rorId>https://ror.org/05mw5ed57</rorId>
  </sponsor>
  <funder id="Funder17516-0">
    <name>Gambro Lundia AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-13T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2008-03-13T00:00:00.000Z">09648950</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study to compare spinal cord stimulator implantation with laser treatment of the heart in patients with chronic angina</title>
      <scientificTitle>An open label, single-centre, randomized trial of spinal cord stimulation vs percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial</scientificTitle>
      <acronym>SPIRIT</acronym>
      <studyHypothesis>Refractory angina pectoris leads to significant morbidity. There is an increasing group of patients with 'refractory angina pectoris' who are unsuitable for conventional revascularization by coronary artery bypass surgery or percutaneous intervention. This patient group often have significant disability, with limiting symptoms, multiple medications, and frequent hospital admissions. 

Treatment options include percutaneous myocardial laser revascularization (PMR) and spinal cord stimulation (SCS). The primary objective of this study was to compare the effect of SCS vs PMR on treadmill exercise time on a modified Bruce protocol over a period of 12 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Total exercise time on a modified Bruce protocol (ETT) at 12 months after SCS compared with PMR. In this study, all tests were terminated by the subject. Both SCS and PMR aim to reduce the frequency and severity of angina, and exercise tolerance is a comparatively objective method of measuring angina-free functional capacity.</primaryOutcome>
      <secondaryOutcome>1. Time to patient-reported angina during exercise test
2. Angina class as measured by the Canadian Cardiovascular Score angina scale
3. Morbidity and mortality
4. Safety profiles of each therapy
5. Health-related quality of life was assessed using questionnaires administered at 3, 12, 24 and 36 month follow-up (disease-specific Seattle Angina Questionnaire, the generic Short Form 36 health survey , and EuroQoL questionnaires)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval was obtained from the Huntingdon Local Research Ethics Committee, UK, prior to study commencement, on 15 August 2000 (ref: H00/557)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09648950</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Version 2.2 dated 5 January 2004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, open, parallel, single-centre, randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a4ccb758-67b1-45f8-baeb-33fee1f20445">
	  <name>Papworth Hospital NHS Foundation Trust</name>
	  <address/>
	  <city>Cambridge</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CB23 3RE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient with limiting angina (Canadian Cardiovascular Society [CCS] III or IV) despite maximally tolerated medical therapy 
2. Documented coronary artery disease (within the last 9 months prior to baseline), which is 
unsuitable for conventional revascularisation techniques
3. Patient has documented reversible ischaemia on nuclear scan (Tc-99 sestamibi) 
4. Patient is limited in daily activities, primarily exercise capability, by their anginal pain 
5. Age 18 or older
6. Patient must understand the therapy and give informed consent
7. Patient must be available for appropriate follow-up times for length of study
8. Non-pregnant women (only women who are post menopausal, surgically sterile or those of 
child bearing potential who are using an acceptable method of contraception) as safety for 
use of SCS during pregnancy or delivery has not been established. Acceptable methods of 
contraception include the following: 
a. Barrier type devices (e.g. female condom, diaphragm and contraceptive sponge) used only in combination with a spermicide 
b. Intrauterine devices (IDUs) 
c. Oral contraceptive agent 
d. Depro-ProveraTM (medroxyprogesterone acetate) 
e. Levonorgestrel implants 
f. Naturally sterile (amenorrheic for at least 1 year) in patients over 50 
Note: Abstinence, the rhythm method or contraception by the partner alone are NOT acceptable methods of contraception</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>1. Patient who is not a candidate for surgical implantation of the spinal cord stimulation system,
and/or not a candidate for a PMR procedure and/or unable to use the SCS device appropriately for treatment
2. Patient who has had one or more major cardiac events within the last 2 months
3. Patient with a myocardial wall thickness &lt;8 mm in the ischaemic area to be treated as verified
by echocardiography
4. Patient with extensive peripheral vascular disease that precludes vascular access required for
PMR
5. Patient on intravenous therapy to control their symptoms
6. Patient who is unlikely to survive for more than 12 months due to non cardiac condition e.g.
malignancy
7. Patient who has other diseases that are considered of greater clinical significance than the
angina pectoris (e.g. inadequately controlled diabetes mellitus, heart failure) that would impact
the ability of the clinician to adequately assess the incremental effects of the trial treatment
8. Patient with ejection fraction of less than 30% as verified by echocardiography
9. Patient with cause of angina other than coronary artery disease (e.g. syndrome "X" patient)
10. Patient who is unable to perform treadmill exercise test per protocol
11. Patient who was previously enrolled in this study, or is currently in another clinical study, which will interfere with this protocol
12. Patient who has had spinal cord stimulation (SCS) therapy, a transmyocardial laser revascularization (TMLR) or PMR procedure in the past
13. Patient with an implanted pacemaker or defibrillator
14. Patient who has medical conditions which may require Magnetic Resonance Imaging (MRI)
15. Patient with a history of dementia or other persisting mental disorders significantly interfering
with ability to cooperate or comply with the requirements of the study or comprehend informed
consent
16. Patient with history of alcohol or drug abuse</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic angina pectoris</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Angina pectoris</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Trial patients were randomised to either Spinal Cord Stimulation System implant (SCS) or Percutaneous Myocardial Laser Revascularisation (PMR). 

The Spinal Cord Stimulation System used for this trial was a Medtronic fully implantable SCS systems. Either Itrel 3 or Synergy implantable generators were used. The spinal cord stimulation lead was chosen by the investigator from any Medtronic commercially available lead approved for use in refractory angina pectoris. The implant was performed according to the instructions in the technical manuals accompanying the devices. The lead was placed such that adequate/optimal paraesthesia was obtained in the area of angina pain. When adequate paraesthesia coverage was obtained the physician went on to permanent implant of the pulse generator. Proper patient education both pre and post implant of the device is essential. The investigator was responsible for adequately and regularly checking the integrity of the system at 3 months, 12 months and then annually. The stimulator should be used prophylactically by the patient for a minimum of 3 hours per day (for example: 3 times per day for a duration of 1 hour each). However, there is no upper limit and the patient may use the device as much as needed. Parameters for this stimulation vary from patient to patient. Therefore, the physician and patient need to work together to establish an effective and tolerable level. The stimulator should also be used at time of anginal attack to treat the pain. A higher level of stimulation may be used for this acute treatment. The maximum tolerable amplitude should be set for such use. However, it is necessary to assure that this level is not uncomfortable or painful. 

For this trial any commercially available Percutaneous Myocardial Revascularisation could be used. An optical fibre is inserted via the femoral artery under local anaesthesia and passed up into the left ventricle. Energy from a Ho:YAG laser is applied to the endocardial surface of the myocardium to vaporise the myocardial tissue and create channels from the endocardial surface into the myocardium. The co-axial system allows the laser to be manipulated in 3 planes giving access to the whole of the left ventricle. The laser position is monitored by fluoroscopy in orthogonal views. Once the position of the laser has been checked in both views, the laser is fired. Two bursts of the laser are used to create a channel 4-6 mm deep, in the myocardium, except in the apex where only one burst is used. The position is marked in both views on acetate sheets attached to the fluoroscopy monitors. Laser channels are created at a minimum of 1 cm apart, and are placed to cover the target region. Typically 10-15 channels are being made.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16554313 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3ecfb6b5-2300-4e80-b1a6-ab84cb9c90b8" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16554313"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17581-0</funderId>
      <contactId>Contact55543_17581</contactId>
      <sponsorId>Sponsor54127</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55543_17581">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Schofield</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Papworth Hospital NHS Foundation Trust
Papworth Everared</address>
      <city>Cambridge</city>
      <country>United Kingdom</country>
      <zip>CB23 3RE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1480 830541</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">peter.schofield@papworth.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54127">
    <organisation>Medtronic Sàrl (Switzerland)</organisation>
    <website>http://www.medtronic.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Route du molliau</address>
      <city>Tolochenaz</city>
      <country>Switzerland</country>
      <zip>CH-1131 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.471158.e</gridId>
    <rorId>https://ror.org/04pf17v09</rorId>
  </sponsor>
  <funder id="Funder17581-0">
    <name>This study was sponsored by Medtronic SA, who were responsible for funding of the trial related investigations such as perfusion scans and treadmill tests, research staff for data collection and travelling expenses for the subjects. The sponsor had no role in study design, data collection and interpretation, or in the decision to submit the above report for publication.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-10T00:00:00.000Z">14206374</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Posture control after lumbar microdiscectomy</title>
      <scientificTitle>Posture control after lumbar microdiscectomy: effect of transmuscular surgical approach and of early postoperative physiotherapy - a randomised clinical trial</scientificTitle>
      <acronym/>
      <studyHypothesis>1. Transmuscular surgical approach causes less damage to postoperative posture control because it does not damage the back muscle insertions
2. Early postoperative physiotherapy improves short and long term posture control</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Muscle control (assessed by postural balance test and sit-to-stand test), assessed in the lab at two weeks, eight weeks and six months post-operatively.</primaryOutcome>
      <secondaryOutcome>Comfort:
1. Back pain
2. Sciatica
3. Functional status
4. Return to work

Secondary outcome measures are assessed by standardised patient questionnaires preoperatively and at two weeks, eight weeks, six months and one year postoperatively.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Commissie Medische Ethiek of Leuven University Hospitals in November 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14206374</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>S50782</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, randomised, single centre trial with four arms (two variables: early specific physio versus later non-specific physio; transmuscular versus paramedian surgical approach).</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-18T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a8b3dae0-262c-42e2-882b-d1bcbd038e75">
	  <name>Department of Neurosurgery</name>
	  <address/>
	  <city>Leuven</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>3000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. One level disc herniation, either L4-L5 or L5-S1, explaining symptoms and representing operative indication. Purely median disc herniations are excluded.
2. Age: 18 - 60 years, either sex
3. Living within 30 km perimeter of the hospital
4. Informed consent signed</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Emergency operation required
2. Litigation, worker's compensation
3. Clinical suspicion of depression or fibromyalgia (the suffering is not exlusively explained by the disc herniation)
4. Previous lumbar surgery, irrespective of the level
5. Significant neurological deficit (weakness worse than 4/5)
6. Systemic disease significantly affecting patient's functioning (American Society of Anaesthesiologists [ASA] grade greater than 3)
7. Median disc herniation
8. Patient unable to communicate in the Dutch language</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (in Dutch).</patientInfoSheet>
      <recruitmentStart>2008-02-18T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sciatica caused by a lumbar disc herniation</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Other intervertebral disc disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Transmuscular surgical approach versus classic paramedian approach to the disc herniation at surgery
2. Early postoperative physiotherapy, starting two weeks postoperatively, and consisting of an individualised program with standardised goals versus 'conservative' treatment: no physiotherapy in the first six weeks post-operation and after six weeks only when indicated

Follow up is one year for all four arms.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17533-0</funderId>
      <funderId>Funder17533-1</funderId>
      <funderId>Funder17533-2</funderId>
      <contactId>Contact55495_17533</contactId>
      <sponsorId>Sponsor54079</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55495_17533">
    <title>Prof</title>
    <forename>Bart</forename>
    <surname>Depreitere</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Neurosurgery
University Hospitals Leuven
Herestraat 49</address>
      <city>Leuven</city>
      <country>Belgium</country>
      <zip>3000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54079">
    <organisation>University Hospitals Leuven (The Netherlands)</organisation>
    <website>http://www.uzleuven.be/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Herestraat 49</address>
      <city>Leuven</city>
      <country>Belgium</country>
      <zip>3000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410569.f</gridId>
    <rorId>https://ror.org/0424bsv16</rorId>
  </sponsor>
  <funder id="Funder17533-0">
    <name>Contribution for logistic expenses:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17533-1">
    <name>Medtronic B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17533-2">
    <name>Stryker Nederland (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-10T00:00:00.000Z">84003996</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of mesalazine to prevent relapse in paediatric crohn&#146;s disease</title>
      <scientificTitle>Prevention of relapse by mesalazine (Pentasa®) in paediatric crohn's disease: a multicentric double-blind randomised placebo-controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>The trial&#146;s primary objective was to compare the efficacy of mesalazine (Pentasa®, Ferring) versus placebo in maintaining remission in paediatric crohn's disease (CD) patients, when used after the successful treatment of an acute episode with either medication alone or parenteral/enteral nutrition techniques combined or not with medication.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical relapse (HB score greater than or equal to 5, if confirmed within two weeks) 
2. Surgery for an acute complication of CD

Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up.</primaryOutcome>
      <secondaryOutcome>Treatment failure, defined as:
1. Relapse
2. Failure of steroid withdrawal (weaning failure)
3. Side-effects intolerance requiring treatment discontinuation
4. Worsening or aggravation of patient status requiring treatment interruption 
5. Initiation of a new treatment as decided by the clinician

Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethcis approval received from the Ethics Committee of Paris VII on the 10th January 1991 (ref: Etude Pentacomp/90/01).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84003996</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Etude Pentacomp/90/91</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A multicentric, double-blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1991-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e3e431c1-1ff0-4c65-9ce5-adb87da73520">
	  <name>Hopital Robert Debré 48 Bd Sérurier</name>
	  <address/>
	  <city>Paris</city>
	  <state/>
	  <country>France</country>
	  <zip>75019</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children less than 18 years old, either sex
2. Diagnosed with crohn&#146;s disease before the age of 16 by means of clinical, radiological, endoscopic and histological data
3. Had to be in an active phase defined by:
3.1. A Harvey Bradshaw score (HB) greater than or equal to 5, and
3.2. An erythrocyte sedimentation rate (ESR) greater than or equal to 25 mm at hour one
4. All lesion localisations, except exclusive anorectal localisation, were included, providing patients&#146; lesion extension had been assessed within two years prior to inclusion

After flare-up treatment, inclusion criteria were as follows: 
1. Patients in clinical remission within six months following flare-up treatment initiation at pre-inclusion
2. An HB score under 5
3. An ESR under 25 mm
4. Normal hepatic and renal functions</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60, extended to 120</totalTarget>
      <exclusion>1. Flare-up had been treated with mesalazine or had required immuno-suppressors
2. Patients with known hypersensitivity to salicylate
3. Patients whose flare-up had occurred at pre-inclusion when on a 5-aminosalicylic acid (5-ASA) dose greater than 50 mg/kg/day for over two months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1991-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Paediatric crohn's disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Crohn's disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>At inclusion, patients were randomised per stratum, within each centre, using random permuted two to four sized-blocks (each centre did not know the size of their own block), to the following:
1. 50 mg/kg/day mesalazine dose 
2. Placebo (identical tablets) 

This was taken over a one-year period. Patients were monitored every three months over a one-year period or until endpoint. 

The study treatment was initiated either one week after the interruption of parenteral or enteral nutrition, or at the end of a sulfalazine or metronidazole treatment, or if the prednisone dose during the steroid weaning period was below 0.2 mg/kg. After the study treatment began, only antispasmodic and antidiarrhoeal agents, as well as sedatives were to be given as possible additional medications. 

Following the recruitment of 57 children from 1991 to 1993, trial results showed a trend favouring mesalazine. Recruitment was consequently resumed from 1996 to 1999.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mesalazine (Pentasa®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17517-0</funderId>
      <contactId>Contact55479_17517</contactId>
      <sponsorId>Sponsor54062</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55479_17517">
    <title>Prof</title>
    <forename>Jean Pierre</forename>
    <surname>Cezard</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hopital Robert Debré 48 Bd Sérurier</address>
      <city>Paris</city>
      <country>France</country>
      <zip>75019</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+33 (0)1 40 03 23 62</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jean-pierre.cezard@rdb.aphp.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54062">
    <organisation>Ferring SA (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>7 rue Jean Baptiste Clément</address>
      <city>Gentilly</city>
      <country>France</country>
      <zip>94250</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487243.e</gridId>
    <rorId>https://ror.org/03vrwsp35</rorId>
  </sponsor>
  <funder id="Funder17517-0">
    <name>Ferring SA (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">02971192</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of acupuncture in pain relief and functional improvement in ankylosing spondylitis: a randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the efficacy of acupuncture for spinal pain relief in patients diagnosed with Ankylosing Spondylitis (AS).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed before and immediately after the interventions: 
1. Patient's assessment of spinal pain (0-10 cm VAS). 
2. Patient's global assessment of disease-activity and function (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Bath Ankylosing Spondylitis Functional Index [BASFI]). The BASDAI measures the severity of fatigue, spinal and peripheral joint pain, localized tenderness, and morning stiffness, assessed on a 10 cm VAS. The BASFI measures the functional status of AS patients, and is also assessed on a 10 cm VAS.
3. Acute-phase reactants (C-Reactive Protein, Erythrocyte Sedimentation Rate [ESR], Immunoglobulin A [IgA]) 
4. Number of analgesic pills per week</primaryOutcome>
      <secondaryOutcome>Subjective assessment of pain, performed before and immediately after the interventions,  using a 7-point Likert scale, where 1 = much worse, 2 = moderately worse, 3 = slightly worse, 4 = no effect, 5 = small improvement, 6 = moderate improvement, 7 = great improvement.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the University Hospital, University of Sao Paulo, School of Medicine, approved on 8 October 2003 (CAPPESQ number: 769-03)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN02971192</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Project number at Institute of Orthopaedics and Traumatology: 371</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, randomised placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4f0cfbb5-a458-484b-9006-d99f84058203">
	  <name>Rua Guaramembé, 589</name>
	  <address/>
	  <city>Sao Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>01308-050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age range between 20 and 60 years 
2. Painful complaints in the axial line 
3. Patients who have not received any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or analgesics for three months prior to the inclusion into this trial
4. Those who are referred to the Rheumatology Service, University of São Paulo, University Hospital, School of Medicine with diagnosis of ankylosing spondylitis according to the New York 15 and European 16 criteria for spondyloarthropathies
5. A mean baseline Visual Analogue Scale (VAS) score &gt;= 4 for pain</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Severe psychiatric disease
2. Sensory or motor neurological deficits
3. Fibromyalgia
4. Previous treatment with acupuncture 
5. Unable to visit the hospital for treatment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pain relief in patients diagnosed with ankylosing spondylitis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Pain relief in patients diagnosed with ankylosing spondylitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomization was performed using colored balls. Patients rated their pain intensity using VAS, disease activity, and function level at baseline. 

Patients were randomly allocated to one of two treatment groups: 

Group A: Classical acupuncture. Participants received classical acupuncture treatment associated with the use of NSAIDs and analgesics. Disposable, sterilized, stainless steel 0.25 mm x 40 mm length needles were employed. 10 acupuncture sessions, twice weekly, 20 minutes per session. Each patient was treated in a separate room. 

Group B: Sham acupuncture. Participants received NSAIDs and analgesics together with non-invasive sham electro acupuncture, which was performed using inactive surface electrodes with audiovisual biofeedback reinforcement, touching patient's skin for seven seconds. 10 acupuncture sessions, twice weekly, 20 minutes per session. Each patient was treated in a separate room. 

Acupuncture points employed in both groups: GV20b, SI3b, BL62b, GB34b and Ex-B2b</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17479-0</funderId>
      <contactId>Contact55441_17479</contactId>
      <sponsorId>Sponsor54021</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55441_17479">
    <title>Dr</title>
    <forename>Liliana</forename>
    <surname>Lourenço Jorge</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Guaramembé, 589 </address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>01308-050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54021">
    <organisation>University of São Paulo (Brazil)</organisation>
    <website>http://www2.usp.br</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>São Carlos
Ribeirão Preto</address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11899.38</gridId>
    <rorId>https://ror.org/036rp1748</rorId>
  </sponsor>
  <funder id="Funder17479-0">
    <name>University of São Paulo, University Hospital (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">25350905</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Topical use of adrenaline in different concentrations for endoscopic sinus surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Vasoconstrictors such as cocaine or epinephrine (adrenaline) are routinely applied during functional endoscopic sinus surgery. The goal is to control bleeding because, when surgery is endoscopic, even minor bleeding can be troublesome if it blocks the small end of the endoscope. Nevertheless vasoconstrictors might cause an increase in blood pressure and heart arrhythmias. The ideal adrenaline concentration should be the one to provide optimal operative field with no cardiovascular side effects. Despite its routine use, that concentration is yet to be determined. Concentrations of adrenaline varying from 1:1000 to 1:200,000 have been used both topically and sub-mucosally. Many studies have used both adrenaline and cocaine, which makes it difficult to establish the individual role of each substance on the outcome. We have decided to work with adrenaline solutions applied only topically. 

We study the effects of topical use of adrenaline solution on the nasal mucosa in three different concentrations on systemic absorption of the drug, blood pressure, heart rhythm, operative bleeding and operative time during endoscopic sinus surgery for nasal polyposis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following data were collected during surgery (No assessment was done post-operatively): 
1. Variation of blood pressure during surgery (measured by non-invasive blood pressure measures every 3 minutes)
2. Variation of heart frequency during surgery (measured continuously by 12 lead ECG)
3. Development of heart arrythmias during surgery (measured continuously by 12 lead ECG)
4. Operative bleeding (measured both objectively by the amount of blood aspirated during the procedure and subjectively by visual-analogue scale from 01 = no bleeding to 10 = very high bleeding)
5. Variation of plasma levels of adrenaline measured by three blood samples obtained during each surgery
6. Operative time</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the ethic committee of Federal University of Rio de Janeiro (UFRJ) on 24 November 2004 (ref: 207/04 CEP)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25350905</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind single-centre controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="621fe6be-6b09-4d98-85fb-170c726beeb8">
	  <name>Praia de Botafogo, 422 / 1106</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>+55 22250 040</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Be over 18 years old
2. Need elective endoscopic sinus surgery under general anesthesia for the treatment of nasal polyposis
3. Understand and give written consent to participate in the trial
4. To be classified as grade I or II according to the American Society of Anesthesiology classification of pre-operative assessment</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>1. Patients legally incompetent or unable, for any reason, to read and sign a written consent form 
2. Patients who withdraw their consent in any time during the course of the trial, even if they have signed the consent form 
3. Patients with systemic hypertension, coronary diseases, heart arrythmia, coagulation disorders, collagen disorders, renal or liver insufficiency in any degree, previously diagnosed or detected during pre-operative assessment 
4. Pregnant women 
5. Patients who do not follow the trial protocol for any reason, unless it is related to the use of the adrenaline solution 
6. Patients in use of a number of medications that might interfere with blood pressure or coagulaion, such as anti-inflammatory drugs, oral hypoglicemics, beta agonists, etc</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Nasal polyposis</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Nasal polyposis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were submitted to endoscopic sinus surgery under general anesthesia for treatment of nasal polyposis using different concentrations of adrenaline solution applied topically to the nasal mucosa. 

Concentrations: 
1. Adrenaline 1:2000 with lidocaine 1% (4 ml)
2. Adrenaline 1:10,000 with lidocaine 1% (4 ml)
3. Adrenaline 1:50,000 with lidocaine 1% (4 ml)

The control group consisted of patients submitted to tonsillectomies using the same anesthetic protocol as the study groups but without the use of adrenaline solution during surgery.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>adrenaline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17366-0</funderId>
      <contactId>Contact55327_17366</contactId>
      <sponsorId>Sponsor53896</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55327_17366">
    <title>Dr</title>
    <forename>Krishnamurti</forename>
    <surname>Sarmento Junior</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Praia de Botafogo, 422 / 1106
Botafogo</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>+55 22250 040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krishnamurti.sarmento@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53896">
    <organisation>Federal University of Rio de Janeiro (UFRJ) (Brazil) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Av. Pedro Calmon, nº 550
Prédio da Reitoria
2º andar
Cidade Universitária </address>
      <city>Rio de Janeiro </city>
      <country>Brazil</country>
      <zip>CEP 21941-901</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8536.8</gridId>
    <rorId>https://ror.org/03490as77</rorId>
  </sponsor>
  <funder id="Funder17366-0">
    <name>Federal University of Rio de Janeiro (UFRJ) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-28T00:00:00.000Z">75155444</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Which intravenous fluid should be given for hospitalized patients?: A prospective randomised study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypothesize of the study is that in sick children, moderately hypotonic fluids (such as fluids contain 77 mmol/L sodium) are better tolerated (i.e. induce less hyponatraemia without the risk of hypernatraemia) than conventional intravenous fluids that contain 34 mmol/L sodium.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Association between administration of hypotonic fluids and hospital-acquired hyponatraemia, assessed by the following:
1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24</primaryOutcome>
      <secondaryOutcome>To determine contributive factors that may increase hyponatraemia risk, assessed by the following: 
1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy. 
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24. 
3. Plasma AntiDiuretic Hormone (ADH), measured at T0. Abnormal ADH function was assessed by serum osmolality and serum sodium determinations.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical Board of Istanbul University, Istanbul Faculty of Medicine, approved on 13 June 2005. Ref: 2005/526.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75155444</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Türkiye</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f4d6d98c-6794-4047-a043-44cc3da8e711">
	  <name>Istanbul University</name>
	  <address/>
	  <city>Istanbul</city>
	  <state/>
	  <country>Türkiye</country>
	  <zip>34390</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All children aged between 3 months to 16 years old who received intravenous fluids</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="16.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Dehydration
2. Cerebral oedema
3. Nephrotic syndrome
4. Hepatorenal syndrome
5. Plasma sodium level below 135 mmol/L
6. Congestive heart failure
7. Renal failure
8. Inborn error of metabolism
9. Protein energy malnutrition
10. Patients receiving mannitol or diuretics
11. Patients whose fluid therapy was started before admission</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyponatraemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hyponatraemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients were randomized to one of the three study arms prospectively. Stratified block randomization was performed, with each one-week block featuring a different intravenous solution. Randomization was performed separately for children on the ward and children in the Paediatric Intensive Care Unit (PICU).

Arm 1: 0.2% sodium in 5% dextrose
Arm 2: 0.3% sodium in 3.3% dextrose
Arm 3: 0.45% sodium in 5% dextrose

When hyponatraemia developed in any group during the therapy intravenous fluid sodium composition was increased and fluid therapy was decreased to 80% of the initial volume.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Intravenous Fluid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16511-0</funderId>
      <contactId>Contact54469_16511</contactId>
      <sponsorId>Sponsor53024</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54469_16511">
    <title>Prof</title>
    <forename>Metin </forename>
    <surname>Karaböcüoğlu</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Istanbul University
Istanbul Faculty of Medicine 
Department of Paediatric Intensive Care
Millet Cad
Fındıkzade	  </address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>34390</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+01190 5332341818</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mkara63@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53024">
    <organisation>Istanbul University, Faculty of Medicine (Turkey)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Paediatric Intensive Care 
Millet Cad
Fındıkzade </address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>34390</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.9601.e</gridId>
    <rorId>https://ror.org/03a5qrr21</rorId>
  </sponsor>
  <funder id="Funder16511-0">
    <name>Mainly investigator-funded with support from Ege Medical Company (Turkey)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-07-10T00:00:00.000Z">99270116</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is laser treatment or surgery the best way of treating varicose veins?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Endovenous laser ablation (EVLA) produces comparable short-term results to surgery (abolition of great saphenous vein [GSV] reflux and improvement in symptoms) for the treatment of primary varicose veins due to sapheno-femoral incompetence with greater saphenous vein reflux.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Abolition of GSV reflux at three months (duplex ultrasound) 
2. Improvement in disease-specific quality of life (Aberdeen Varicose Vein Questionnaire)</primaryOutcome>
      <secondaryOutcome>1. Time to return to work and to normal activity
2. Pain and analgesia use during first week following treatment
3. Overall satisfaction and satisfaction with cosmetic outcome
4. Generic quality of life (36-item Short Form health survey [SF-36]) at 1 and 12 weeks following treatment
5. Complications</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received from Leeds (West) Research Ethics Committee in May 2003 (ref: 03/052).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99270116</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VS03/2281</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Parallel group, non-blinded, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-06-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9cfbfbd3-f2c9-4de3-a383-9f1bd0ab14ff">
	  <name>Leeds Vascular Institute</name>
	  <address/>
	  <city>Leeds</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LS1 3EX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Symptomatic varicose veins 
2. Primary sapheno-femoral incompetence with greater saphenous vein reflux</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>342</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>342</totalTarget>
      <exclusion>1. Unable to consent
2. Children (under 18 years)
3. Unfit for general anaesthesia
4. Recurrent varicose veins
5. Patients on long-term anticoagulation
6. Patients with anterior thigh branch of greater saphenous vein arising within 10 cm of groin and competent GSV distal to this</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-06-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Varicose veins</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Varicose veins</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Endovenous laser treatment (810 nm diode laser, Diomed) versus sapheno-femoral ligation, greater saphenous vein stripping and avulsions (surgery).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18278775 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c53e0951-6902-41b7-baa3-d782cc85afe7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18278775"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16614-0</funderId>
      <funderId>Funder16614-1</funderId>
      <contactId>Contact54572_16614</contactId>
      <sponsorId>Sponsor53127</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54572_16614">
    <title>Mr</title>
    <forename>Michael</forename>
    <surname>Gough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leeds Vascular Institute
The General Infirmary at Leeds
Great George Street</address>
      <city>Leeds</city>
      <country>United Kingdom</country>
      <zip>LS1 3EX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53127">
    <organisation>Leeds Teaching Hospitals NHS Trust (UK)</organisation>
    <website>http://www.leedsteachinghospitals.com/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Leeds Vascular Institute
The General Infirmary at Leeds
Great George Street</address>
      <city>Leeds</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>LS1 3EX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.415967.8</gridId>
    <rorId>https://ror.org/00v4dac24</rorId>
  </sponsor>
  <funder id="Funder16614-0">
    <name>Leeds Teaching Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16614-1">
    <name>Diomed Ltd (UK) - part of research fellow salary paid (£15,000 pa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-05-02T00:00:00.000Z">48222371</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study on the effects on plasma insulin and glucose after a single meal replacement in patients with type two diabetes mellitus</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>A single oral doses of amino acids may play a role as insulin secretagogues.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Insulin and glucose response</primaryOutcome>
      <secondaryOutcome>Hormones involved in glucose homeostasis</secondaryOutcome>
      <trialWebsite>http://www.chdr.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48222371</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, placebo controlled crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9802d8e7-18ec-4b64-9120-d3bab077a0f9">
	  <name>Center for Human Drug Research</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 CL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult Type two Diabetes Mellitus (T2DM) patients</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Insulin use
2. Significant clinical abnormalities</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes, insulin response</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention with single meals with different composition of amino acids in a double-blind placebo controlled trial.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Plasma insulin, glucose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16479-0</funderId>
      <contactId>Contact54437_16479</contactId>
      <sponsorId>Sponsor52992</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54437_16479">
    <title>Dr</title>
    <forename>J.</forename>
    <surname>Burggraaf</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Center for Human Drug Research
Zernikedreef 10</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 CL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52992">
    <organisation>Dutch State Mines (DSM) (The Netherlands)</organisation>
    <website>http://www.dsm.com/en_US/html/about/about_us_home.htm</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 6500</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 JH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10760.30</gridId>
    <rorId>https://ror.org/00k01kt20</rorId>
  </sponsor>
  <funder id="Funder16479-0">
    <name>Dutch State Mines (DSM) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-04-11T00:00:00.000Z">54960762</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>LIMIT-1: Lowering the Incidence of vascular complications with Metformin in patients with Impaired glucose Tolerance and a recent transient ischaemic attack or minor ischaemic stroke: a phase II randomised, controlled trial</title>
      <scientificTitle/>
      <acronym>LIMIT-1</acronym>
      <studyHypothesis>Metformin will be tolerated in patients with Transient Ischaemic Attack (TIA) or minor ischaemic stroke and will result in blood glucose lowering.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Tolerability of metformin treatment (measured as number of patients still on treatment after three months)
2. The safety of metformin treatment (which will be continuously monitored) 
3. The adjusted difference in two-hour post-load glucose levels at three months

Primary outcomes will be measured at three months for feasability (safety will be continuously monitored). Primary outcome on effect on post-load glucose level will be measured at three months, expressed as a for baseline adjusted difference in mean two-hour post-load glucose levels at three months between treatment groups.</primaryOutcome>
      <secondaryOutcome>1. Differences in fasting glucose levels
2. Insulin resistance
3. Body mass index
4. Percentage of patients with a normal glucose tolerance at three months

Secondary outcomes will be measured at three months, as a for baseline adjusted difference between groups.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received from the Medical Ethics Committee of Erasmus Medical Centre on the 5th December 2006 (ref: NL15011.078.06 [local METC number MEC-2006-303]).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN54960762</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, open-label, multicentre, controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b57f755c-57b2-4d06-b9c3-12697e9e00e9">
	  <name>Stroke Research Assistant</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 DR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men or women 18 years and over
2. TIA/minor ischaemic stroke (modified Rankin Score three or less) within six months
3. Impaired fasting glucose (fasting glucose level of 5.6 to 6.9 mmol/L) and/or impaired glucose tolerance (two-hour post-load glucose level of 7.8 to 11.0 mmol/L)
4. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Known or newly diagnosed diabetes mellitus
2. Contraindication for metformin:
2.1. Renal impairment (serum creatinine greater than 135 micromol/L for men, and greater than 110 micromol/L for women)
2.2. Hepatic disease (liver enzymes increased twice the upper limit of normal)
2.3. A past history of lactic acidosis
2.4. Cardiac failure requiring pharmacological therapy
2.5. Chronic hypoxic lung disease
2.6. Pregnancy
2.7. Breast feeding
3. Severe comorbidity interfering with follow-up</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Transient ischaemic attack or minor ischaemic stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Vascular complications</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised for metformin or no oral anti-diabetic drug (open-label) on top of optimal standard treatment, including lifestyle advice aimed at weight reduction and regular physical exercise.

Patients allocated to metformin will be treated with metformin for three months from the day of randomisation until study end. They will start with a daily dose of 500 mg that will be slowly increased in one-month time to a daily dose of 2,000 mg in two gifts. All patients will be followed for three months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Metformin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16389-0</funderId>
      <contactId>Contact54347_16389</contactId>
      <sponsorId>Sponsor52901</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54347_16389">
    <title>Ms</title>
    <forename>Esther</forename>
    <surname>van der Heijden</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Stroke Research Assistant
Erasmus Medical Centre
Room Ee 22.42
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 408 7818</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">stroke-research@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52901">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Neurology
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder16389-0">
    <name>Erasmus Medical Centre (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-01-22T00:00:00.000Z">43202606</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fatty Acid Absorption Study</title>
      <scientificTitle/>
      <acronym>FAAS</acronym>
      <studyHypothesis>The biochemical importance of dietary lipids to human physiology and nutrition is now firmly established and research continues to show potential health benefits of polyunsaturated fatty acids (PUFAs) and in particular the omega 3 fatty acids from fish and precursors of the same family found in many plant oils. Current UK recommendations advise the public to eat at least two portions of fish every week including one of oily fish, which is rich in omega-3 PUFAs, or take more than 200 mg/day of omega-3 PUFAs.  According to the World Health Organization (WHO), one portion should provide an equivalent of 200-500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In fact most people in the UK consume considerably less than one portion per week indicating that the recommended levels are not being achieved leaving fish oil supplementation as the most convenient route to augment dietary intake.  However, reaching recommended intake levels may require taking several capsules of fish oil per day. An alternative is to use a more palatable version of liquid fish oils presented as a flavoured emulsion, which may offer a more flexible route to achieve the required level of intake.

Approximately 95% of dietary lipids ingested from foods consist of triacylglycerols (TAGs) and lipid digestion is initiated by the action of lingual/gastric lipases which, together with the physical mixing action of the stomach, produces small partially emulsified droplets containing mainly TAGs but also free fatty acids (FFA) and diacylglycerols. Further emulsification together with the action of pancreatic lipase results in the production of 2-monoacylglycerols (sn2-MAG) and free fatty acids and these are incorporated into mixed micelles before passive diffusion into the enterocyte. Once inside the enterocyte the fatty acids with less than 12 carbon atoms pass directly into the hepatic portal vein. However, most dietary fatty acids have a chain length greater than 12 and these are re-synthesised into TAG and incorporated into the chylomicron (CM) family of lipoproteins which are secreted into the lymphatic system and transported to the thoracic lymphatic duct where they enter the circulation. The fatty acid composition of the core of the CM - TAG generally reflects the dietary fatty acid profile, particularly in the first four to six hours postprandial period. The CM-TAG are rapidly hydrolysed by lipoprotein lipase (LPL) releasing between 70 and 90% of the total TAG and leaving CM remnants which are removed from the plasma via low density lipoprotein (LDL) receptors in the liver. There have been conflicting observations that the use of emulsified forms of fish oils in some studies has led to improved digestion and absorption of EPA and DHA with other studies showing no differences in absorption.

Preliminary research in our laboratory has indicated that both the rate and extent of absorption of the fatty acids EPA and DHA improve if the oil is pre-emulsified prior to ingestion. This cross over absorption study was designed to establish whether pre-emulsification of an oil mixture leads to improved absorption of fatty acids, particularly DHA and EPA, compared with the non-emulsified form of the oil mixture.

The hypothesis of this trial is that absorption of fatty acids occurs more rapidly and extensively in a pre-emulsified form than in the straight oil.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Plasma fatty acid concentrations.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received by the local research ethics committee (Lechyd Morgannwg Health) on the 2nd October 2002.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43202606</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2002.112</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised cross-over study with oral ingestion of a fatty acid mixture in the form of an oil mixture or a water miscible oil emulsion.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-02-14T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b6f1d0e-2985-46e1-9b80-bf8d7e9d0fed">
	  <name>Obsidian Research Limited</name>
	  <address/>
	  <city>Port Talbot</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SA12 7BZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>1. Healthy volunteers, male or female
2. Body mass index (BMI) less than 30
3. Capable of providing written informed consent
4. Not pregnant or subject to medication</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Involved in dietary control
2. Obese/very low body weight
3. Hypercholesterolemic
4. Taking dietary fatty acid supplements</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-02-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Absorption of fatty acids as part of a healthy dietary lifestyle</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Absorption of fatty acids</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In a cross-over study, participants were randomly assigned to receive either the oil mixture or oil emulsion mixture, with thirteen subjects receiving oil and eleven subjects receiving oil emulsion in the first stage. The mixtures of oils (comprising concentrated fish oil 43%, borage oil 31% and flaxseed oil 26%) in both the natural form and in the emulsified form were supplied by Cultech Ltd., Port Talbot, United Kingdom.

The participants fasted for 12 hours prior to the study. Subjects consumed 30 ml of oil as part of a meal comprising fat free cereal (37.5 g), skimmed milk (230 ml), sugar (4 g) and apple juice (150 ml). For the remainder of the nine hour collection period the participants ate only boiled rice (100 g), boiled pasta (100 g) and fresh fruit (large apple). Apple juice or water was available to drink throughout the day. The average energy intake was 3596 kJ (859 kcal) comprising 147 g carbohydrate, 23 g protein and 32 g total fat. Twenty days later (washout period), the procedure was repeated with the assignments reversed.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17254329 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d6f0da26-8a35-4162-b098-b2b16676b090" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-01-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17254329"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16035-0</funderId>
      <contactId>Contact53981_16035</contactId>
      <sponsorId>Sponsor52530</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53981_16035">
    <title>Dr</title>
    <forename>Sue</forename>
    <surname>Plummer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Obsidian Research Limited
Unit 2 Christchurch Road
Baglan Industrial Park</address>
      <city>Port Talbot</city>
      <country>United Kingdom</country>
      <zip>SA12 7BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52530">
    <organisation>Obsidian Research Limited (UK)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Unit 2 Christchurch Road
Baglan Industrial Park</address>
      <city>Port Talbot</city>
      <country>United Kingdom</country>
      <zip>SA12 7BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder16035-0">
    <name>Funded in-house by Cultech Limited with financial support from Welsh Development Agency as part of Technology Exploitation Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-09-26T00:00:00.000Z">92152389</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A clinical feasibility study to evaluate the effectiveness and safety of VivescOs™ as bone graft for reconstruction of intra-oral osseous defects</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Cultured mesenchymal stem cells differentiated into osteoblasts and seeded on scaffolds can induce bone formation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety of VivescOs™ has been confirmed.</primaryOutcome>
      <secondaryOutcome>Efficacy of VivescOs™ is doubted.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN92152389</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Clinical feasability study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Other</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-11-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="249a2c1c-6aff-411c-bfab-83163d6a43b2">
	  <name>University Medical Centre Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Repair of the intra-oral defect was indicated as preparation for dental implant placement in a secondary stage.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Presence of local or systemic disease;
2. Pregnancy, cancertherapy; 
3. Previous participation in another trial within 30 days; 
4. Known hypersensitivity for penicillin, streptomycin.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-11-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intra-oral bone defects, loss of teeth/molars</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Intra-oral bone defects, loss of teeth/molars</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>VivescOs™ versus tissue engineered bone.

Preoperatively, four weeks before the implantation procedure, a aspiration biopsy will be taken.

Post-operatively patients will be evaluated using radiographic analysis by OphtoPantomoGrams (OPG), histological analysis by biopsy specimens and clinical evaluation of functionality at three months, six months, nine months, 12 months and 15 months after surgery.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>VivescOs™</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15415-0</funderId>
      <contactId>Contact53348_15415</contactId>
      <sponsorId>Sponsor51895</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53348_15415">
    <title>Dr</title>
    <forename>Gert</forename>
    <surname>Meijer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht (UMCU)
AZU
Department of Oral Maxillofacial Surgery
Heidelberglaan 100
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gmeijer@azu.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51895">
    <organisation>IsoTis NV (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Prof. Bronkhorstlaan 10-D</address>
      <city>Bilthoven</city>
      <country>Netherlands</country>
      <zip>3723 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.422884.0</gridId>
    <rorId>https://ror.org/04qce9v53</rorId>
  </sponsor>
  <funder id="Funder15415-0">
    <name>IsoTis NV (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-09-26T00:00:00.000Z">47031769</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Study of the efficacy of topically applied cyclosporin solution on psoriatic nails</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of the study is to establish and evaluate the affectivity of topical application of cyclosporin in psoriasis of the fingernails.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Nail Psoriasis Severity Index (NAPSI) scores.</primaryOutcome>
      <secondaryOutcome>1. Prevention 
2. Does the NAPSI correlate with patient satisfaction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47031769</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="32d5c572-1626-42ff-b9bc-25aa0fe29742">
	  <name>Postbus 2040</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinical diagnosis of  psoriasis of fingernails in both hands
2. In cases of oral treatment with  methotrexate, prednisone or fumarates, the dose of medication before the start  has to be constant for eight weeks and it may be reasonably expected that the dose shall not be altered during the treatment phase of the study
3. A minimum of at least two affected nails on the left hand and the right hand, and the number of affected nails may differ by one nail at the maximum on the left hand compared with those on the right hand</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Systemic treatment with cyclosporine or a biological agent (efaluzimab, etanercept or related medication)
2. Change of oral medication eight weeks before the start of the trial
3. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Psoriatic nails</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Psoriatic nails</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>On left and right fingernails either placebo, or 100 mg/ml cyclosporin application, twice daily.
The duration of the treatment is till complete cure or for a maximum of 16 weeks.
Control group maximal 28 weeks</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cyclosporin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15416-0</funderId>
      <contactId>Contact53349_15416</contactId>
      <sponsorId>Sponsor51896</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53349_15416">
    <title>Dr</title>
    <forename>Annik</forename>
    <surname>van Rengen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Postbus 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4634569</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.vanrengen@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51896">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15416-0">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-09-26T00:00:00.000Z">07851536</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Information processing, neuropsychological, and neurobiological processes in pediatric obsessive-compulsive disorder</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Information-processing:
1. Changes in measures of severity of Obsessive-Compulsive Disorder (OCD) are explained (partially) by changes in measures of meta-cognitions (explicit and/or implicit)
2. Changes in measures of meta-cognitions (explicit and implicit) precede changes in measures of severity of OCD

Neuropsychological processes:
1. Changes in measures of severity of OCD are explained (partially) by changes in measures of inhibition of attentional processes
2. Changes in measures of inhibition precede changes in measures of severity of OCD

Neurobiological processes:
1. Volumes of prefrontal cortex and striatum, activity of anterior cingulate, orbitofrontal region and striatum differ from healthy controls and change during treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Severity of OCD (CY-BOCS, measured at the start of the waitlist condition, directly before start of the CBT, session eight, 16 and follow up after 16 weeks)
2. Anxiety/Depression (Revised Child and Anxiety Depression Scale [RCADS]) measured at the start of the waitlist, directly before start of the CBT, at the end of the therapy (session 16) and follow up after 16 weeks)</primaryOutcome>
      <secondaryOutcome>1. Information-processing (explicit: Revised 44 item version of the Obsessive-Beliefs Questionnaire scale [OBQ-44 R], Meta-Cognitions Questionnaire for Adolescents [MCQ-A], Implicit: Implicit Association Procedure [IAP]) (measured at the start of the waitlist, directly before start of the CBT, session eight and 16 and follow up after 16 weeks)
2. Inhibition/selective attention (dot-probe, measured at the start of the waitlist, directly before start of the CBT, session eight and 16 and follow up after 16 weeks)
3. Neuroimaging data: volumes grey and white matter, activity on planning (tower of London), selective attention (Flanker) and inhibition (dot-probe) task in fMRI</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07851536</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="47cb03c5-9dc2-4d84-a711-40c4219c4e85">
	  <name>Academic Medical Center (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children and adolescents eight to 18 years
2. Primary diagnosis: Obsessive Compulsive Disorder (OCD)
3. OCD symptoms for more than six months
4. Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) total score more than 16
5. IQ (Intelligence Quotient) more than 80
6. Informed consent of parents and child</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>45</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>45</totalTarget>
      <exclusion>Use of the following medication: 
1. Selective Serotonin Reuptake Inhibitor (SSRI)
2. Tricyclic Antidepressant (TCA)
3. Anti-psychotic medication

For neurobiological measures (functional Magnetic Resonance Imaging [fMRI]): 
1. Claustrophobia
2. Metal on body</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obsessive-Compulsive Disorder  (OCD)</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Obsessive Compulsive Disorder (OCD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 16 weekly sessions Cognitive Behavioral Therapy (CBT)
2. Waitlist (eight weeks) followed by 16 weekly sessions CBT</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15417-0</funderId>
      <contactId>Contact53350_15417</contactId>
      <sponsorId>Sponsor51897</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53350_15417">
    <title>Ms</title>
    <forename>L H</forename>
    <surname>Wolters</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center (AMC)
Department of Child and Adolescent Psychiatry
Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5662242</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.h.wolters@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51897">
    <organisation>Academic Medical Center (AMC) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder15417-0">
    <name>Academic Medical Center (AMC) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003180</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-06-26T00:00:00.000Z">12814243</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Self-help parent-training for conduct problems in children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Children in the treatment group will show significantly fewer behavioural problems than children in the control group at post-treatment and six-month follow-up as measured by parent and teacher report.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Child behaviour problems as measured by parent's report and teacher's report post-treatment and at six-month follow-up</primaryOutcome>
      <secondaryOutcome>1. Utilisation of mental health services after treatment
2. Parental mental health
3. Parents' sense of competence in parenting
4. Parent's self-report of parenting practices
5. Families' satisfaction with treatment
6. Parent report of parental relationship quality</secondaryOutcome>
      <trialWebsite>http://www.apsoc.ox.ac.uk/EBIG.html</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by National Health Service (NHS) Oxfordshire Research Ethics Committee C, reference number 05/Q1606/57.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12814243</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00299442</clinicalTrialsGovNumber>
      <protocolSerialNumber>05/Q1606/57</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="315a2ae3-3e7f-4560-8ce1-4229eaa35653">
	  <name>University of Oxford</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX1 2ER</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Families with children aged 2-5, on the waiting lists of child and adolescent mental health service clinics, and scores in the clinical range on the standardised measure of child behavioural problems. At least one parent in each family must be literate and a fluent English speaker to participate because the self-administered intervention will primarily consist of written instructions and information in English.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="2.0"/>
      <upperAgeLimit unit="Years" value="5.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70 (100 subjects will be recruited to allow for dropout)</totalTarget>
      <exclusion>1. Clients whose children score below a clinical cut-off score on a standardised measure of child behaviour problems. This is to ensure that participants are appropriate for an intervention aiming to reduce behaviour problems.
2. Non-English speakers or those who are unable to read cannot be included because reading English is required to complete the self-administered intervention
3. Children or parents with severe disabilities and children with a developmental disorder (e.g. autism) will be excluded because the version of the parent-training programme that will be implemented is not designed for families with these types of problems
4. Children who live with a temporary carer will be excluded because the intervention is designed for full-time parents and follow-up will be after one year
5. Children or parents who are currently receiving treatment for psychological problems will be excluded because outcomes may be influenced by interventions not affiliated with this project</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Behavioural problems in children</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Behavioural problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Please note that, as of 18/03/2008, the anticipated end date was updated from 01/10/2007 to 31/08/2008. 

This project will introduce a self-help parent-training programme for families on NHS waiting lists for child mental health services. It will examine whether access to treatment can be increased by providing an intervention that requires fewer resources and by releasing clinician time for more serious cases. This intervention will be tested in a randomised, controlled trial in which 35 subjects will receive treatment and 35 will not. All families will also complete questionnaires before and after treatment in order to measure changes in child behaviour, parenting, and parental-mental health. Cost-effectiveness of this programme will also be analysed. Intention-to-treat analyses will be conducted. 

The control group will receive the self-help intervention after the intervention group completes their post-treatment outcome assessments. The treatment intervention is a self-help version of the Triple P parenting programme and will consist of six parent-training videos and a workbook that will be divided into 10 weeks of treatment, to be completed at home by the families. This intervention is based on social learning theory and provides information about preschoolers' development, promoting acceptable behaviour and responding to unacceptable behaviour in effective ways, promoting children's self-esteem and coping with stress. The control group will receive no treatment during this period. 

Both groups will remain on the waiting list for treatment in a clinic and will commence that treatment if they still wish to do so when they reach the end of the waiting list, regardless of their position in the trial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16437442&amp;query_hl=1&amp;itool=pubmed_docsum Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="565431c3-5d83-4364-8fbd-065ddc6533bd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-01-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16437442&amp;query_hl=1&amp;itool=pubmed_docsum"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12882-0</funderId>
      <contactId>Contact50388_12882</contactId>
      <sponsorId>Sponsor48757</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50388_12882">
    <title>Ms</title>
    <forename>Gretchen</forename>
    <surname>Bjornstad</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Oxford
Department of Social Policy and Social Work
Barnett House
32 Wellington Square</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX1 2ER</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 270342</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gretchen.bjornstad@socres.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48757">
    <organisation>University of Oxford (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Paul Montgomery
Deparment of Social Policy and Social Work
Barnett House
32 Wellington Square</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX1 2ER</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 280325</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">paul.montgomery@socres.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder12882-0">
    <name>University of Oxford Research Development Fund and Oxfordshire Health Services Research Committee (OHSRC) Grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-06-22T00:00:00.000Z">25438351</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double-blind, active-controlled, randomized, parallel group multicentric study to investigate the safety, tolerability and efficacy of reparagen - a dietary supplement compared to glucosamine sulphate in patients with moderate osteoarthritis of the knee</title>
      <scientificTitle/>
      <acronym>REPVGLUOA</acronym>
      <studyHypothesis>That reparagen is safe and effective in patients with moderate osteoarthritis, and compared to glucosamine sulphate, reparagen has a faster onset of action with an overall greater response.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pain visual analogue score
2. Modified Western Ontario and McMaster University osteoarthritis index (WOMAC)</primaryOutcome>
      <secondaryOutcome>1. Serum insulin-like growth factor-1 (IGF-1)
2. Global assessment of therapy
3. Patient's opinion
4. Consumption of rescue medication</secondaryOutcome>
      <trialWebsite>http://www.santerra-pharma.com</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Institutional Ethics Committee of KJ Somaiya Medical College and Hospital, Mumbai, India, submitted on 30/12/2005, approved on 08/02/2006</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25438351</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VL/050421/SP</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind, active-controlled, randomized, parallel group multicentric study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1b347a48-8896-4a84-a6cc-ef500b11b40f">
	  <name>Vedic Lifesciences</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>400 053</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Ambulatory adult patients of either sex &gt;20 years of age
2. Patients with moderate osteoarthritis of the knee, clinically detected and/or diagnosed as per radiological examination and American Rhematology Association (ARA) functional classification
3. ARA functional class II or III
4. Kellgren Lawrence for knee osteoarthritis grade II, grade III
5. Patient's assessment of overall pain score between 40 and 100 mm on a pain-visual analogue scale after washout period</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Arthritis other than osteoarthritis
2. Arthroscopy of either knee in the past year
3. Administration of intraarticular steroids within the past three months or hyaluronic acid in the last nine months
4. Known adverse responses to non-steroidal anti-inflammatory drugs (NSAIDs), suspected hypersensitivity, allergy or other contraindication to any compounds present in the study medication
5. Significant gastrointestinal (GI) diseases or previous GI upset to NSAID administration
6. Pregnant or lactating women or woman of child-bearing age not following adequate contraception
7. Evidence of severe renal, hematopoetic disease or severe cardiac insufficiency as revealed by laboratory investigations and other tests
8. Moderate to severe peripheral neuropathy or other neurological disorders
9. Unwilling or unable to come to regular follow-up studies
10. Any condition which in the opinion of the investigator does not justify patient inclusion in the study
11. Inability to give informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Moderate osteoarthritis of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Reparagen, a combination of a cat's claw extract (Uncaria guianensis), a herbal medicine from the Amazon, and RNI 249, an extract of maca (Lepidium meyenii) a vegetable native to the Andes compared to glucosamine sulphate</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Reparagen, glucosamine sulphate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17974032 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="30d4c240-17ba-4dba-b961-4a907f196053" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-31T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17974032"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15074-0</funderId>
      <contactId>Contact52911_15074</contactId>
      <sponsorId>Sponsor51461</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52911_15074">
    <title>Mr</title>
    <forename>Jayesh</forename>
    <surname>Chaudhary</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vedic Lifesciences
118 Morya House
Off Link Road
Andheri (West)</address>
      <city> Mumbai</city>
      <country>India</country>
      <zip>400 053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)22 5693 9757</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jayesh@ayuherbal.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51461">
    <organisation>Santerra Pharmaceuticals LLC (USA)</organisation>
    <website>http://www.santerra-pharma.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Santerra Pharmaceuticals LLC
12721 Strickland Road</address>
      <city>Raleigh</city>
      <country>United States of America</country>
      <zip>27613</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 919 847 2221</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pbobrowski@santerra-pharma.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15074-0">
    <name>Santerra Pharmaceuticals LLC (USA)  - contracted by Rainforest Nutritionals, Inc.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-03-30T00:00:00.000Z">42445141</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prospective, randomised trial comparing fluids and dobutamine optimisation of oxygen delivery in high-risk surgical patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We aimed to investigate the effect of oxygen delivery index (DO2I) optimisation with fluids versus with fluids and dobutamine on 60-day hospital mortality and incidence of complications.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To evaluate the effect of both DO2I optimisation with fluids compared to with fluids and dobutamine on 60-day mortality in high-risk general surgery patients.</primaryOutcome>
      <secondaryOutcome>The incidence of complications, particularly adverse cardiovascular events.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics board on the 13th May 2002 (ref: 2611/2002).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42445141</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2611/2002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbb7f3b6-21e3-4b48-ac00-f0a97c44c9fc">
	  <name>Av Faria Lima 5416</name>
	  <address/>
	  <city>São Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>15091/000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients older than 18 years old undergoing elective surgeries with greater than or equal to three points according to a risk scoring system adapted from the American College of Cardiology (ACC) or the American Heart Association (AHA) guidelines</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>98</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>98</totalTarget>
      <exclusion>1. Refusal of consent
2. Haemodynamic instability prior to surgery
3. Congestive heart failure
4. Presence of infection
5. Acute myocardial ischaemia prior to enrolment
6. Life expectancy lower than 60 days
7. Disseminated malignancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>High-risk patients undergoing prolonged surgery</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>High-risk surgical patients</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Therapy consisted of pulmonary artery catheter (PAC)-guided haemodynamic optimisation during the operation and 24 hours postoperatively, using either fluids alone or fluids and dobutamine with the aim of achieving supranormal values (oxygen delivery index [DO2I] greater than 600 ml/min/m^2).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dobutamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16696864 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="eb6370aa-1d7b-4662-90b8-caa7272906cf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16696864"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14940-0</funderId>
      <contactId>Contact52739_14940</contactId>
      <sponsorId>Sponsor51278</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52739_14940">
    <title>Prof</title>
    <forename>Suzana</forename>
    <surname>Lobo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Av Faria Lima 5416
Jardim Universitário
São José do Rio Preto</address>
      <city>São Paulo</city>
      <country>Brazil</country>
      <zip>15091/000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51278">
    <organisation>Faculty of Medicine of São José do Rio Preto (FAMERP) Foundation (Brazil)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Av. Brigadeiro Faria Lima, 5416
Vila São Pedro</address>
      <city>São Paulo</city>
      <country>Brazil</country>
      <zip>15091/000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.419029.7</gridId>
    <rorId>https://ror.org/052e6h087</rorId>
  </sponsor>
  <funder id="Funder14940-0">
    <name>Faculty of Medicine of Sao Jose do Rio Preto Foundation (Fundacao Faculdade de Medicina de Sao Jose do Rio Preto [FAMERP] - Hospital de Base) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-03-08T00:00:00.000Z">10791836</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of an educational program on the prevention of complicated infections in patients with diabetes</title>
      <scientificTitle/>
      <acronym>DELPHI</acronym>
      <studyHypothesis>A health education program for both patients and general practitioners will change behaviour by 15%.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Self-reported behaviour with regard to the uptake of measures relevant to patients and healthcare providers on the basis of the developed educational program.</primaryOutcome>
      <secondaryOutcome>The following outcomes are assessed both in persons with diabetes and in primary health care providers:
1. Awareness of the possibility of an abnormal course and a specific treatment of common infections in persons with diabetes
2. Knowledge about infections and prevention of an abnormal course in persons with diabetes
3. Attitude towards infections in persons with diabetes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10791836</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>U03/175-P230</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2625d266-a6f4-4008-b0d2-df93244c5e27">
	  <name>University Medical Center Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 AB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with type 2 diabetes
2. Aged 45 years or older 
3. Able to attend a meeting and without a Dutch language barrier</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>2400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2400</totalTarget>
      <exclusion>Patients greater than or equal to 85 years.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urinary tract infections, lower respiratory tract infections</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention group of patients and general practitioners participates in an educational program on urinary tract and lower respiratory tract infections. The control group doesn&#146;t receive any intervention, but is managed according to usual care. The intervention period is five months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18056887 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fa0830ac-401a-409d-b432-d78f58664a36" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18056887"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14883-0</funderId>
      <funderId>Funder14883-1</funderId>
      <contactId>Contact52663_14883</contactId>
      <sponsorId>Sponsor51196</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52663_14883">
    <title>Ms</title>
    <forename>Leonie M.A.J.</forename>
    <surname>Muller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht (UMCU)
Julius Center for Health Sciences and Primary Care
Str. HP. 6.131
P.O. Box 85060</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2538181</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.m.a.muller@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51196">
    <organisation>University Medical Center Utrecht (The Netherlands)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder14883-0">
    <name>Public Health Fund (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14883-1">
    <name>Diabetes Fund (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-01-30T00:00:00.000Z">07286796</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness and cost-effectiveness of public access defibrillation in urban and rural populations in Northern Ireland</title>
      <scientificTitle/>
      <acronym>Northern Ireland Public Access Defibrillation (NIPAD)</acronym>
      <studyHypothesis>Training laypersons such as first responders and police officers to carry and use automated external defibrillators to attend the scene of out-of-hospital sudden cardiac arrests will result in the resuscitation of additional patients by a reduction in the response time compared to the existing emergency medical service response.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Survival after hospital discharge following out-of-hospital sudden cardiac arrest
2. Cost-effectiveness of public access defibrillation in the study areas</primaryOutcome>
      <secondaryOutcome>1. Reduction in response time compared to existing emergency medical services
2. Return of spontaneous circulation
3. The modelling of the results to Northern Ireland as a whole using a spatial modelling approach
4. The modelling of the effectiveness and cost-effectiveness of public access defibrillation across Northern Ireland</secondaryOutcome>
      <trialWebsite>http://www.med.qub.ac.uk/nipad</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Northern Ireland Research Ethics Committee on the 26th March 2003 (ref: 47/03).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07286796</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>COM/2371/03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An observational study for one year followed by an intervention using public access defibrillation on the cohort</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-03T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Northern Ireland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7a4040e6-3a07-41bf-b4c3-62c61018cd42">
	  <name>QUB Centre For Clinical and Population Science</name>
	  <address/>
	  <city>Belfast</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BT12 6BA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients with a presumed out-of-hospital sudden cardiac arrest over the age of 14 in Antrim, Ballymena, Magherafelt and North and West Belfast district council areas of Northern Ireland.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300,000 people in study area, expected 300 cardiac arrests</totalTarget>
      <exclusion>Out-of-hospital sudden deaths due to non-cardiac causes including trauma, drowning, overdose, poisoning and fire.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-03T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Out-of-hospital sudden cardiac arrest</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cardiac arrest</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Training lay cardiac first responders and police officers to carry and use automated external defibrillators in response to sudden out-of-hospital cardiac arrest in fixed and mobile locations.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17540690 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7836ea51-5d18-48ca-bc90-e78be31b0a25" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17540690"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14619-0</funderId>
      <contactId>Contact52375_14619</contactId>
      <sponsorId>Sponsor50885</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52375_14619">
    <title>Prof</title>
    <forename>Frank</forename>
    <surname>Kee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>QUB Centre For Clinical and Population Science
1st Floor Mulhouse building
Royal Victoria Hospital
Grosvenor road</address>
      <city>Belfast</city>
      <country>United Kingdom</country>
      <zip>BT12 6BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)28 90632746</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.kee@qub.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50885">
    <organisation>The Research and Development Office for Health and Personal Social Services in Northern Ireland (UK)</organisation>
    <website>http://www.centralservicesagency.n-i.nhs.uk/display</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>R&amp;D Office
12-22 Linenhall street</address>
      <city>Belfast</city>
      <country>United Kingdom</country>
      <zip>BT2 8BS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)28 90553617</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joanne.O'Neill@rdo.n-i.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.412915.a</gridId>
    <rorId>https://ror.org/02tdmfk69</rorId>
  </sponsor>
  <funder id="Funder14619-0">
    <name>The Research and Development Office for Health and Personal Social Services in Northern Ireland (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">28577651</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intervention project Osteogenesis Imperfecta (OI) type I and IV: home based training program to increase exercise capacity, muscle strength and aspects of quality of life in children with Osteogenesis Imperfecta</title>
      <scientificTitle/>
      <acronym>ETOI</acronym>
      <studyHypothesis>Children with Osteogenesis Imperfecta type I and IV would benefit from a gradual training program. Increased exercise capacity and muscle strength could increase quality of life.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Exercise capacity and muscle strength.</primaryOutcome>
      <secondaryOutcome>Health related quality of life.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28577651</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>04/331-k (METC UMCU)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, single-blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-02-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-08-02T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b35c6d21-d68c-4848-9a7d-b032e2897b40">
	  <name>KB 02.056.0, 3508 AB</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 EA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Osteogenesis Imperfecta Type I and IV
2. Between 8 and 18 years of age 
3. Ambulatory</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Osteogenesis Imperfecta type II and III
2. Retardation
3. Non-walking</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-02-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-08-02T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteogenesis Imperfecta</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteogenesis imperfecta</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Training program for 12 weeks (two times/week).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18154911 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ba9bc6ae-da99-44b1-b5e0-d2d6835aa3bf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18154911"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14339-0</funderId>
      <funderId>Funder14339-1</funderId>
      <contactId>Contact52225_14339</contactId>
      <sponsorId>Sponsor50753</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52225_14339">
    <title>Dr</title>
    <forename>R.H.H.</forename>
    <surname>Engelbert</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>KB 02.056.0, 3508 AB
P.O. Box 85090</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 EA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2504030</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.engelbert@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50753">
    <organisation>University Medical Centre Utrecht (UMCU) (Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>PO Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder14339-0">
    <name>Johanna Child Fund (Johanna Kinderfonds) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14339-1">
    <name>Foundation for paediatric rehabilitation (Stichting Bio-Kinderrevalidatie) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">33274262</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dutch Acarbose Intervention Trial (DAISI)</title>
      <scientificTitle/>
      <acronym>DAISI</acronym>
      <studyHypothesis>Approximately 1/3 of persons with impaired glucose tolerance (IGT) develops type 2 diabetes mellitus in 5 - 10 years time. Acarbose is an alpha-glucosidase inhibitor decreasing post-prandial glucose levels, without the risk of hypoglycemia. The prevention of diabetes with acarbose in this study was considered a feasible approach.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Venous plasma glucose level two hours after oral intake (in five minutes) of 75 g glucose dissolved in 300 ml water at study end (ie, after three years). A difference in two hour post-load glucose level between placebo and acarbose group of 0.5 mmol/L was regarded as being clinically relevant.</primaryOutcome>
      <secondaryOutcome>1. Fasting venous glucose level
2. Appearance of type 2 diabetes mellitus and normal glucose tolerance, according to WHO criteria
3. B-cell function and insulin sensitivity as assessed via the method of the hyperglycaemic clamp
4. Level of cardiovascular risk factors: cholesterol, high density lipoprotein (HDL)cholesterol, triglycerides, lipoprotein (a) (later deleted by amendment no. 4), albumin/creatinine ratio in time assessed urine sample</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN33274262</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="33df032e-443f-4929-b611-f8347f5cbcd6">
	  <name>Department of general practice</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Persons with impaired glucose tolerance on the basis of two oral glucose tolerance tests (World Health Organization [WHO] 1985 criteria).</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>119</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>119</totalTarget>
      <exclusion>1. Not having side effects of acarbose in the qualification period of three months
2. Persons having endocrinological diseases, or having a malignancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes Mellitus type II (DM type II)</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Acarbose used at a fixed dose of 50 mg. The daily maintenance dose was 50 mg three times a day (tid), which was reached as from week 3 after two weeks of up-titration with 50 mg once a day (od) (week 1) and 50 mg twice daily (bid) (week 2).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14369-0</funderId>
      <contactId>Contact52136_14369</contactId>
      <sponsorId>Sponsor50549</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52136_14369">
    <title>Dr</title>
    <forename>Giel</forename>
    <surname>Nijpels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of general practice
EMGO Institute
VU University Medical Center
Van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 4449659</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.nijpels@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50549">
    <organisation>Bayer Medical B.V. (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 80</address>
      <city>Mijdrecht</city>
      <country>Netherlands</country>
      <zip>3640 AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491169.2</gridId>
    <rorId>https://ror.org/01442sk86</rorId>
  </sponsor>
  <funder id="Funder14369-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-19T00:00:00.000Z">61223447</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective (sero-)epidemiological study on contact transmission and chemoprophylaxis in leprosy</title>
      <scientificTitle/>
      <acronym>COLEP</acronym>
      <studyHypothesis>Rifampicin is an effective chemoprophylactic intervention method to prevent leprosy among close contacts of leprosy patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure is the number of new leprosy patients emerging from the contact groups. The proportions between the rifampicin and the placebo group will be compared at two-years intervals.</primaryOutcome>
      <secondaryOutcome>Analysis will be carried out in order to define special groups at risk. The results of the serological tests will also be compiled and analysed. The number of leprosy patients found in the referent group will be used to calculate the prevalence rate (at intake) and the incidence rate (during follow-up) in the general population, allowing for calculation of relative risks among the contacts.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61223447</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Bangladesh</country>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dac36d64-78cb-4dbe-a0a8-f82a39ef6744">
	  <name>Erasmus Medical Centre Rotterdam</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 DR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients should give consent for approaching their contacts for the trial.
Inclusion criteria for contacts:
1. Those living in the same house
2. Those living in a house sharing the same kitchen
3. First neighbours
4. Close business or social contacts, including other relatives. To be included into this category one has to be in contact with the patient on a daily base (five or more days a week) and during several hours a day.
5. Second neighbours

All divided into spouse, child, parent, sibling, other relative, relative-in-law, non-relative.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20,000</totalTarget>
      <exclusion>Exclusion criteria for contacts:
1. Any contact who refuses to be included
2. Any contact being pregnant
3. Any contact currently on tuberculosis (TB) or leprosy treatment (however, released from treatment [RFT] patients should be included)
4. Any contact below 5 years of age
5. Any contact suffering from jaundice
6. Any contact living only temporarily in the area
7. Any contact found to suffer from leprosy at the initial survey
8. Any contact already enrolled in the study via the contact</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Leprosy</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Leprosy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All close contacts of 1000 consecutive new leprosy patients in the districts of Nilphamari and Rangpur (Bangladesh) who are recruited for the study are considered for inclusion. A contact group consists of around 20 individuals. 

A single dose of rifampicin or a placebo is given to all included contacts. The rifampicin comes in capsules of 150 mg and the dosage is the same as recommended in the guidelines of the national leprosy control programme of Bangladesh and DBLM. According to bodyweight and age, two to four capsules are taken by the contact under direct supervision of a DBLM staff member. All the contacts of one patient receive medication from the same container.

Dosage of rifampicin according to age and body weight: 
Adult greater than 35 kg: 600 mg
Adult less than 35 kg: 450 mg
Child 10 - 14 years:  450 mg
Child 5 - 9 years: 300 mg</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rifampicin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18332051 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4d2f561d-be32-4879-8e20-f350fa545fff" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-04-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18332051"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14302-0</funderId>
      <funderId>Funder14302-1</funderId>
      <contactId>Contact52049_14302</contactId>
      <sponsorId>Sponsor50513</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52049_14302">
    <title>Dr</title>
    <forename>F.J.</forename>
    <surname>Moet</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Centre Rotterdam
Department of Public Health
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.moet@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50513">
    <organisation>Erasmus Medical Centre (The Netherlands) </organisation>
    <website>http://www.erasmusmc.nl/content/englishindex.htm</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Public Health 
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder14302-0">
    <name>The Leprosy Mission International (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14302-1">
    <name>American Leprosy Missions (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-02T00:00:00.000Z">13964268</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>FIC - Training in malaria research in Uganda</title>
      <scientificTitle/>
      <acronym>FIC</acronym>
      <studyHypothesis>The proportion of convulsions terminated by buccal midazolam is higher than the proportion of convulsions terminated by rectal diazepam in children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time taken to terminate convulsion within 10 minutes without re-occurence of the convulsion in an hour.</primaryOutcome>
      <secondaryOutcome>1. Time taken to re-occurence of convulsion after initial control
2. Time taken to terminate the convulsion within 10 minutes
3. Proportion of children who get respiratory depression within one hour after adminstration of the study drug</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approved received from: 
1. The Makerere University Medical School Research and Ethics Review Board (Uganda)
2. National Council of Science and Technology Institutional Review Board (IRB) (Uganda)
3. University of California San Francisco Institutional Review Board (IRB) (USA)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13964268</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double blind clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Uganda</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1fc5c10e-b5eb-4239-9514-054476f4e806">
	  <name>Makerere Univeristy</name>
	  <address/>
	  <city>Kampala</city>
	  <state/>
	  <country>Uganda</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 3 months to 12 years
2. Admission to Acute Care Unit during the study period
3. A child who presents to the Acute Care Unit with convulsions
4. Provision of informed consent to continue participation in the study</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="12.0"/>
      <gender>Both</gender>
      <targetEnrolment>350</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>350</totalTarget>
      <exclusion>1. Documented evidence of having recieved parenteral anticonvulsant in the past 24 hours
2. Cessation of convulsion before adminstration of study drug
3. Parent/caretaker verbally declines to participate in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prolonged convulsions</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Rectal diazepam versus buccal placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Midazolam, diazepam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18166545 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a93498cb-f2b4-4363-9945-a1a79119a78a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18166545"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14195-0</funderId>
      <contactId>Contact51909_14195</contactId>
      <sponsorId>Sponsor50338</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51909_14195">
    <title>Dr</title>
    <forename>Justus</forename>
    <surname>Byarugaba</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Makerere Univeristy
Faculty of Medicine
Department of Pediatrics and Child Health
P.O. Box 7072</address>
      <city>Kampala</city>
      <country>Uganda</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+256 75 696 633</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">byarugabaj@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50338">
    <organisation>Fogarty International Center (FIC) (USA)</organisation>
    <website>http://www.fic.nih.gov/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>National Institutes of Health
Office of Communications
Building 31, Room B2C29
31 Center Drive
MSC 2220</address>
      <city>Bethesda</city>
      <country>United States of America</country>
      <zip>20892-2220</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 301 496 2075</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ficinfo@nih.gov</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453035.4</gridId>
    <rorId>https://ror.org/02xey9a22</rorId>
  </sponsor>
  <funder id="Funder14195-0">
    <name>Fogarty International Centre (FIC) (USA) (grant ref: TW007375)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-11-25T00:00:00.000Z">88861431</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Study of safety and immunogenicity of Measles vaccine (Rouvax®) administered by transcutaneous route (France)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received on the 23rd March 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88861431</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC 037</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-03-23T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5728d984-e44e-428a-9fc3-34ebd890c27f">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy adults between 18 and 22 years of age of haplotype HLA-A201 who have previously been immunised against measles and for whom the anti-measles antibodies are low
2. Female participants must be under contraception</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. Previous infection with measles
2. Contra-indications to the use of Rouvax® vaccine
3. Hypersensitivity to egg proteins
4. Human Immunodeficiency Virus (HIV) seropositive
5. Treatment with corticosteroids or immunosuppressors in 15 days prior to enrolment
6. Exposure of back-skin to sun in 15 days prior to enrolment
7. Dermatological pathology on back
8. Acute and evolutive disease
9. Blood donation in three months prior to enrolment
10. In a period of exclusion following previous clinical trials
11. Having received 3800 or more Euros in preceeding 12 months from participation in clinical trials</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-03-23T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vaccine/immunisation</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: 1 dose of Rouvax® vaccine administered to the skin of the shoulder after stripping (abrading) the skin
Control: 1 dose of Rouvax® administered by injection</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Measles vaccine (Rouvax®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14243-0</funderId>
      <contactId>Contact51966_14243</contactId>
      <sponsorId>Sponsor50396</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51966_14243">
    <title>Dr</title>
    <forename>Martin</forename>
    <surname>Friede</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4398</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">friedem@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50396">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14243-0">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-19T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-06-15T00:00:00.000Z">41383109</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Scottish Childhood Obesity Treatment Trial</title>
      <scientificTitle/>
      <acronym>SCOTT</acronym>
      <studyHypothesis>To test whether a novel (intensive and behavioural) dietetic intervention for childhood obesity was more successful than standard care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Body mass index (BMI) standard deviation score.

Outcomes measured at baseline, +6 months after start of intervention and +12 months after start of intervention.</primaryOutcome>
      <secondaryOutcome>1. Objectively measured habitual physical activity and sedentary behaviour (accelerometry)
2. Waist circumference standard deviation score
3. Quality of life

Outcomes measured at baseline, +6 months after start of intervention and +12 months after start of intervention.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41383109</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cdfce78c-332e-44b1-9f3c-bd56b94e5164">
	  <name>Reader in Paediatric Energy Metabolism</name>
	  <address/>
	  <city>Glasgow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>G3 8SJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Obese (body mass index [BMI] greater than 98th percentile) children of primary school age (5 - 11 years at baseline), referred for treatment for their obesity.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="5.0"/>
      <upperAgeLimit unit="Years" value="11.0"/>
      <gender>Both</gender>
      <targetEnrolment>134</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>134</totalTarget>
      <exclusion>1. Non obese
2. Family apparently not willing to attempt lifestyle changes
3. Having special educational needs
4. Receiving treatment for obesity elsewhere</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obesity</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Obesity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: 
Intensive behavioural approach to treatment (eight appointments over six months; 5 - 6 hours patient/family contact time).

Control: 
Standard dietetic care (1 - 1.5 hours patient/family contact time over six months).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18310175 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="377f8a90-d896-4db8-b913-3fb67838ba21" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18310175"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13024-0</funderId>
      <contactId>Contact50554_13024</contactId>
      <sponsorId>Sponsor48933</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50554_13024">
    <title>Dr</title>
    <forename>John J</forename>
    <surname>Reilly</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Reader in Paediatric Energy Metabolism
University of Glasgow Division of Developmental Medicine
1st Floor Tower Block QMH
Yorkhill Hospitals</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G3 8SJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jjr2y@clinmed.gla.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48933">
    <organisation>Yorkhill Hospitals NHS Trust (UK)</organisation>
    <website>http://www.nhsggc.org.uk/content/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Yorkhill</address>
      <city>Glasgow</city>
      <state>Scotland</state>
      <country>United Kingdom</country>
      <zip>G3 8SJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Morlet.Meinertz@yorkhill.scot.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13024-0">
    <name>Chief Scientist Office of the Scottish Executive Health Department (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">73698240</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre field trial of ofloxacin-containing Multidrug Therapy (MDT) in leprosy (Philippines)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73698240</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>920335</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Philippines</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4160aded-c599-4285-8bb9-b16a8607ac94">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients suspected of leprosy without previous treatments with MDT or ofloxacin in dermatological consultation and referred to the Leprosy Unit.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. Patients with provincial addresses, temporary addresses and temporary works
2. Patients not residing in targeted areas for the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Leprosy</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Leprosy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Therapeutic efficacy of new MDT regimen containing Ofloxacin, in comparison with the standard World Health Organization (WHO)/MDT regimen among paucibacillary (PB) and multibacillary (MB) leprosy patients.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ofloxacin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder12973-0</funderId>
      <contactId>Contact50496_12973</contactId>
      <sponsorId>Sponsor48874</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50496_12973">
    <title>Dr</title>
    <forename>V.E.</forename>
    <surname>Pannikar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pannikerv@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48874">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12973-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">88133880</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase I clinical trial to evaluate the safety and immunogenicity of aluminium hydroxide precipitated autoclaved Leishmania major (Alum-ALM) + Bacillus Calmette-Guerin (BCG) combined with sodium stibo-gluconate (SSG) compared with SSG alone in the treatment of post kala azar dermal leishmaniasis (Sudan)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88133880</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A30468</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sudan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f6f2e05f-735a-405d-b022-707dceaf82d6">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Males and females 7 - 60 years
2. Skin rash of greater than six months duration following a history of successful treatment for Visceral Leishmaniasis (VL)
3. Absence of other skin conditions
4. Positive Direct Agglutination Rest (DAT) or rk39
5. Willing for hospitalisation at Khartoum for 90 days
6. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Pregnant or lactating women
2. Concurrent/chronic illness
3. Known allergy to vaccine components
4. Other allergies requiring steroids and Levamisole
5. Known immunological deficiency-including human immunodeficiency virus (HIV)
6. Concurrent participation in any other drug or vaccine trial
7. Known or planned vaccination within one month prior to study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dermal leishmaniasis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Dermal leishmaniasis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Alum-ALM and BCG combined with sodium stibo-gluconate (SSG)
Control group: Sodium stibo-gluconate (SSG)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>Aluminium hydroxide precipitated autoclaved Leishmania major (Alum-ALM) + Bacillus Calmette-Guerin (BCG) + sodium stibo-gluconate (SSG)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder12976-0</funderId>
      <contactId>Contact50499_12976</contactId>
      <sponsorId>Sponsor48877</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50499_12976">
    <title>Dr</title>
    <forename>S</forename>
    <surname>Naozin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">naozins@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48877">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12976-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">48141450</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of World Health Organisation (WHO) cardiovascular disease (CVD)-risk management package - scenario one (Sri Lanka)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48141450</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC050</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-05-07T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sri Lanka</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5fd0eb71-2960-48c5-a0d9-c4cd6a21fff6">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 30 - 70 years
2. Currently not under treatment for hypertension
3. Systolic blood pressure between 140 and 179 mmHg measured twice with a 5 to 10 minute interval
4. Informed consent given</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. Pregnancy
2. Trauma (injury) as presenting complaint
3. Renal diseases: nephropathy, renal artery stenosis
4. Endocrinological (hormonal) disorders: phaechromocytoma, Cushing syndrome, Conn syndrome, acromegaly
5. Coarctation of the aorta
6. Use of steroids and/or non-steroidal anti-inflammatories (NSAIs)
7. All acute conditions presenting with bleeding, pain, diarrhoea, vomiting, breathing disorders and circulatory disorders
8. Inability to comply with the follow-up requirements
9. Inability to provide informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-05-07T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>20 primary health care facilities.
10 facilities to apply the study protocol based on Scenario One of the WHO CVD-Risk Management Package (intervention sites).
Other 10 to continue with conventional treatment or usual care (control sites).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder12983-0</funderId>
      <contactId>Contact50506_12983</contactId>
      <sponsorId>Sponsor48884</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50506_12983">
    <title>Dr</title>
    <forename>S</forename>
    <surname>Mendis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mendiss@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48884">
    <organisation>The Department of Cardiovascular Diseases (CVD)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12983-0">
    <name>The Department of Cardiovascular Diseases (CVD)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">13670619</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparative study of the bactericidal and sterilising activity of three fluoroquinolones: gatifloxacin, moxifloxacin and ofloxacin substituted for ethambutol in the two month initial phase of the standard anti-tuberculosis treatment regimen also containing rifampicin, isoniazid and pyrazinamide (South Africa)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13670619</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC078</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-25T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9eb2f0ba-8eb1-4516-924d-aaec5b05457c">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male/female of 18-65 years
2. Weight 38-80 kg
3. Recently microscopically diagnosed pulmonary TB
4. Findings in medical history and physical examination not exceeding grade 2
5. Voluntarily signed informed consent
6. Confirmed negative pregnancy test at the screening visit
7. Willing to use effective contraceptive methods during treatment
8. Normal lab values not exceeding grade 2, except haemoglobin &lt;6.5 g/dl and potassium &lt;3.0 mEq/l (&gt;grade 1)
9. Consent for a pre-screening biological test to exclude possible Multi Drug Resistant (MDR) TB and Negative MDR TB screen test will be a check if pre-screening biological test is done</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="65.0"/>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. History of TB within the last 3 years
2. Concomitant infection requiring additional anti-infectious treatment (especially anti-retroviral medication [ARV])
3. Human immunodeficiency virus (HIV) infected patients at World Health Organisation (WHO) stage 4
4. Diabetes mellitus or non insulin dependent diabetes mellitus requiring treatment
5. Drug and alcohol abuse
6. History of drug hypersensitivity and/or active allergic disease
7. Impaired renal, hepatic or gastric function that may interfere with drug absorption, distribution, metabolism or elimination</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-25T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tuberculosis (TB)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control
Regimen 1: Standard TB treatment (isoniazid, rifampicin, pyrazinamide and ethambutol)

Interventions
Regimen 2: Isoniazid, rifampicin, pyrazinamide and gatifloxacin
Regimen 3: Isoniazid, rifampicin, pyrazinamide and ofloxacin
Regimen 4: Isoniazid, rifampicin, pyrazinamide and moxifloxacin</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Gatifloxacin, moxifloxacin and ofloxacin, ethambutol, rifampicin, isoniazid and pyrazinamide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder12986-0</funderId>
      <contactId>Contact50511_12986</contactId>
      <sponsorId>Sponsor48888</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50511_12986">
    <title>Dr</title>
    <forename>T</forename>
    <surname>Kanyok</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kanyokt@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48888">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12986-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">03184072</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled trial to assess the efficacy of expedited cataract extraction in the prevention of falls in elderly people awaiting cataract surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine whether cataract surgery reduces the risk of falls in elderly people.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Time to first fall
2. Mean fall frequency over 12 months after randomisation
3. Visual acuity
4. Visual disability (VF-14)
5. Barthel Index
6. London handicap scale
7. EuroQOL questionnaire
8. Formal and informal care costs</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03184072</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RBF 98XX7 (N0192080943)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="55c41f31-9c4d-498f-b43d-218f3337f392">
	  <name>Health Care of the Elderly</name>
	  <address/>
	  <city>Nottingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NG7 2UH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Female patients awaiting cataract surgery
2. Aged 75 - 85 years</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Female</gender>
      <targetEnrolment>400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>400</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cataract surgery in elderly people</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Cataract</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Expedited versus routine cataract surgery</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18172067 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fe35a6dd-2f6f-4e68-a5f7-41cb021141c1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18172067"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6063-0</funderId>
      <contactId>Contact7488_6063</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7488_6063">
    <title>Mr</title>
    <forename>A</forename>
    <surname>Foss</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Health Care of the Elderly
A Floor
East Block
University Hospital
Queens Medical Centre</address>
      <city>Nottingham</city>
      <country>United Kingdom</country>
      <zip>NG7 2UH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6063-0">
    <name>NHS Executive Trent (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2003-10-22T00:00:00.000Z">43755713</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Remifentanil versus fentanyl for analgesia-based sedation to provide patient comfort in the intensive care unit</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>This randomised, double-blind study compared the safety and efficacy of remifentanil (REMI - 9 mcg/kg/h) with fentanyl (FEN - 1 mcg/kg + 1.5 mcg/kg/h). One hundred and ninety six Intensive Care Unit (ICU) subjects with normal renal function or mild renal impairment requiring mechanical ventilation were studied. A pre-defined dosing algorithm permitted initial titration of the opioid followed by the addition of propofol (0.5 mg/kg/h) if required. A REMI-based regimen was very effective in the provision of optimal sedation and analgesia. The mean % hours of optimal sedation was 88.3% in the REMI group. Similar results were observed when using FEN. There was no statistically significant difference in the overall between-subject variability in the duration of optimal sedation. However for those subjects who achieved a Sedation Agitation Scale (SAS) score of four, variability was significantly lower when using REMI. 

Propofol was not required in 65% of subjects. When propofol was administered there was a trend towards less use in remifentanil subjects. The dosing algorithm facilitated rapid extubation in both treatment groups. REMI provided comparable haemodynamic stability compared to FEN. The adverse event profile observed for REMI was similar to FEN and was not unexpected for ICU subjects receiving an opioid agonist. The pharmacokinetic (PK) profile of REMI was unaltered in subjects with renal impairment. Although the elimination half-life of remifentanil acid was doubled and the clearance was reduced by half in subjects with mild renal impairment, no evidence of prolonged opioid effects were seen. REMI is therefore considered to effective and well tolerated in ICU subjects.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Between-subject variability around the mean percentage of hours of optimal sedation (Sedation Agitation Scale [SAS] score of 4).</primaryOutcome>
      <secondaryOutcome>Efficacy: 
1. Mean percentage of hours subjects were optimally sedated (SAS score of 4) during the treatment and post-treatment periods 
2. Mean percentage of hours subjects were inadequately sedated (SAS score of 5, 6 or 7) during the treatment and post-treatment periods 
3. Mean percentage of hours subjects were excessively sedated (SAS score of 1, 2 or 3) during the treatment and post-treatment periods 
4. Mean percentage of hours subjects were dangerously agitated (SAS score of 7) during the treatment and post-treatment periods 
5. Mean percentage of hours subjects were unarousable (SAS score of 1) during the treatment and post-treatment periods 
6. Mean percentage of hours of no/mild pain during the treatment and post-treatment periods 
7. Time between start of the extubation process and actual extubation 
8. Total time on mechanical ventilation within the treatment period 
9. Time between extubation and ICU discharge 
10. Time from the start of study drug until ICU discharge 

Other:
1. Weighted mean infusion rates of remifentanil, fentanyl and propofol 
2. Total exposure to study opioid and propofol including frequency of opioid infusion rate changes, and propofol infusion rate changes (from starting the opioid infusion until it was discontinued) 
3. Incidence of supplementary open-label propofol and fentanyl bolus doses administered for stimulating procedures during the treatment period 
4. Incidence of open-label propofol and fentanyl bolus doses administered for rescue treatment during the maintenance phase 
5. Incidence of supplementary open-label propofol, fentanyl, morphine and bupivacaine bolus doses administered for analgesia/sedation during the extubation and post-extubation phases

Safety: 
1. Haemodynamic parameters during and after treatment (mean arterial pressure [MAP] and heart rate [HR]) 
2. Respiratory function (post-extubation only - respiratory rate [RR], fractional inspired oxygen concentration [FiO2] and peripheral oxygen saturation [SpO2]) 
3. Clinical adverse events

Pharmacokinetics: 
Remifentanil and remifentanil acid blood concentrations.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from local and national ethics committees.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43755713</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>USA30206</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-07-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-06-19T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
	<country>England</country>
	<country>Germany</country>
	<country>Netherlands</country>
	<country>Spain</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c4f63a5a-393c-490a-b483-fb95e49704b8">
	  <name>GlaxoSmithKline</name>
	  <address/>
	  <city>Middlesex</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>UB6 0HE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>A subject will be eligible for inclusion in this study only if all of the following criteria apply: 
1. Admitted into the ICU within the previous 24 hours 
2. Intubated and expected to require short-term mechanical ventilation (i.e. for at least a further 12 hours and up to 72 hours after starting the study drug infusion) 
3. Aged over 18 years old 
4. A female is eligible to enter and participate in this study if she is of: 
4.1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal) or, 
4.2. Child-bearing potential, has a negative pregnancy test (urine or serum) at screen, and agrees to one of the following: 
4.2.1. Complete abstinence from intercourse from two weeks prior to administration of study drug, throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the investigational drug (minimum of 7 days) 
4.2.2. Female sterilisation 
4.2.3. Sterilisation of male partner 
4.2.4. Implants of levonorgestrel
4.2.5. Injectable progestogen
4.2.6. Oral contraceptive (combined or progestogen only) 
4.2.7. Any intrauterine device (IUD) with published data showing that the highest expected failure rate is less than 1% per year (not all IUDs meet this criterion) 
4.2.8. Any other methods with published data showing that the highest expected failure rate for that method is less than 1% per year
4.2.9. Barrier method only if used in combination with one of the above methods 
5. Weighs an estimated 120 kg or less 
6. Informed consent: a signed and dated written informed consent or assent must be obtained from the subject or the subject's legally acceptable representative, respectively, prior to study participation 
7. Language: fluent and literate in the language spoken by the investigator and staff</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>152</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>152</totalTarget>
      <exclusion>A subject will not be eligible for inclusion in this study if any of the following criteria apply: 
1. Concurrent medications: 
1.1. Requires neuromuscular blocking agents to facilitate mechanical ventilation 
1.2. Has or is likely to receive an epidural block during the maintenance phase 
2. The use of remifentanil, fentanyl or propofol is contraindicated 
3. Concurrent disease or disorder:
3.1. Has or is likely to require a tracheostomy within 96 hours after admission to the ICU 
3.2. Has a neurological disease or other medical condition that may affect the ability to assess the SAS score and PI (e.g. stroke, stupor or coma, dementia) 
3.3. Predicted creatinine clearance of &lt;50 mL/min indicating moderate or severe renal impairment 
3.4. Modified ICU admission simplified acute physiology score (SAPS) II score of greater than 43 
4. Drug allergy:  history of allergic hypersensitivity to fentanyl analogues, morphine, benzodiazepines or propofol 
5. History of alcohol abuse 
6. History of drug abuse: clinically significant abuse of opioid or sedative containing substances, defined as: 
6.1. Patterns of substance intake consistent with disruption of normal function in society 
6.2. Past or current impairment of organ function reasonably related to substance intake
7. Previous entry into this study or participation in any other investigational drug study within 30 days of randomisation 
8. Concurrently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device 
9. Protocol specified treatment regimens would be inappropriate for the management of the subject 
10. The subject will have been in the ICU for longer than 24 hours at the time of starting the study drug infusion</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-07-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-06-19T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Analgesia in the critically ill</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Analgesia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Assessment of sedation and pain scores with initial titration of the opioid to effect, monitoring of haemodynamics.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Remifentanil, fentanyl</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/14975049 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="49a3045b-d8cb-465a-a57d-8b7adea3ae74" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/14975049"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5714-0</funderId>
      <contactId>Contact7145_5714</contactId>
      <sponsorId>Sponsor5308</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7145_5714">
    <title>Dr</title>
    <forename>Andrew</forename>
    <surname>Kirkham</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>GlaxoSmithKline
Greenford Road
Greenford</address>
      <city>Middlesex</city>
      <country>United Kingdom</country>
      <zip>UB6 0HE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)208 966 3919</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andrew.jt.kirkham@gsk.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5308">
    <organisation>GlaxoSmithKline (UK)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Greenford Road
Greenford</address>
      <city>Middlesex</city>
      <country>United Kingdom</country>
      <zip>UB6 OHE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0) 208 966 3919</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andrew.jt.kirkham@gsk.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.418236.a</gridId>
    <rorId>https://ror.org/01xsqw823</rorId>
  </sponsor>
  <funder id="Funder5714-0">
    <name>GlaxoSmithKline (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/100004330</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-17T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2003-09-12T00:00:00.000Z">86810172</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised trial of Polytetrafluoroethylene (PTFE) patch saphenoplasty in patients having surgery for recurrent long saphenous varicose veins</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the use of a PTFE patch with normal repair for surgery for recurrent varicose veins.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To reduce the re-recurrence rate after reoperative surgery for recurrent long saphenous varicose veins.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86810172</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0106092280</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="08179204-6390-460e-8ad8-c155b0e2d320">
	  <name>Consultant Surgeon</name>
	  <address/>
	  <city>Gloucester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>GL1 3NN</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>At least 50 patients having surgery for recurrent long saphenous varicose veins.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Surgery: Long saphenous varicose veins</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Long saphenous varicose veins</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Polytetrafluoroethylene patch
2. Flush ligation</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17512226 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9748bf0c-0b4b-4f12-abb4-008f884b80d8" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17512226"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5363-0</funderId>
      <contactId>Contact55570_5363</contactId>
      <sponsorId>Sponsor5287</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55570_5363">
    <title>Mr</title>
    <forename>Jonathan</forename>
    <surname>Earnshaw</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Consultant Surgeon
Gloucestershire Royal Hospital
Great Western Road</address>
      <city>Gloucester</city>
      <country>United Kingdom</country>
      <zip>GL1 3NN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5287">
    <organisation>Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5363-0">
    <name>Gloucestershire R&amp;D Consortium (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2003-09-12T00:00:00.000Z">79246957</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The use of ultrasound guidance in embryo transfer to improve success rates in assisted conception - a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. To determine whether ultrasound guidance improves pregnancy and implantation rates significantly.
2. To assess the effect of ultrasound on patients and caregivers satisfaction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Successful pregnancy outcome</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79246957</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0128117383</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-10-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-10-23T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5140c173-c9e7-495b-9849-8b5c723b7529">
	  <name>Liverpool Women's Hospital</name>
	  <address/>
	  <city>Liverpool</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>L8 7SS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All women having embryo transfer will have access to participation:
1. Women less than 38 years old receiving fresh embryos
2. Women less than 38 years old receiving frozen embryos
3. Women greater than 38 years old receiving fresh embryos 
4. Women greater than 38 years old receiving frozen embryos</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>2000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2000</totalTarget>
      <exclusion>Does not comply with above inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-10-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-10-23T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>In vitro fertilisation (IVF)</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Artificial fertilisation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Ultrasound-guided embryo transfer 
2. Non-ultrasound-guided embryo transfer</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18325883 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="103a5abf-2a97-42fe-a840-074f2540acf6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18325883"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5370-0</funderId>
      <contactId>Contact6667_5370</contactId>
      <sponsorId>Sponsor5287</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact6667_5370">
    <title>Dr</title>
    <forename>Andrew</forename>
    <surname>Drakely</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Liverpool Women's Hospital
Crown Street

</address>
      <city>Liverpool</city>
      <country>United Kingdom</country>
      <zip>L8 7SS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 0151 708 8899</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5287">
    <organisation>Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5370-0">
    <name>Liverpool Womens Hospital NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2001-10-18T00:00:00.000Z">09719705</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Which treatment for low back pain? A factorial randomised controlled trial comparing intravenous analgesics with oral analgesics in the emergency department and a centrally acting muscle relaxant with placebo over three days</title>
      <scientificTitle/>
      <acronym>BAPA</acronym>
      <studyHypothesis>Objectives:
1. To compare the effectiveness of intravenous non-steroidal analgesics with oral non-steroidal analgesics for acute treatment in the Emergency Department  (ED) (Stage 1)
2. To compare the effectiveness of either arm with the effectiveness in those patients who refused to be randomised but agreed to participate in the patient preference trial with the treatment of their choice
3. To compare the effectiveness of a centrally active muscle relaxant with placebo given for three days after presentation to the ED (Stage 2)
4. To compare the effectiveness of either arm with the effectiveness in those patients who refused to be randomised but agreed to participate in the patient preference trial with the treatment of their choice</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain assessed by means of the VAS. For stage one, the VAS is evaluated immediately before and 90 minutes after treatment, for stage two, the VAS is evaluated on day four.</primaryOutcome>
      <secondaryOutcome>1. The Roland Morris disability questionnaire (RMDQ)
2. 36-item short form health survey (SF-36)

Stage one is evaluated immediately before treatment by personal interview, then, for stage two, the RMDQ and the SF-36 is evaluated four days after enrolment. Patients will be interviewed by telephone using the structured format of the questionnaires of RMDQ and SF-36.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The protocol was approved by the ethics committee of the Vienna Medical Faculty.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09719705</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Austria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c13e19da-7691-47ac-8aa0-d78a67bb3d36">
	  <name>Universitätsklinik für Notfallmedizin</name>
	  <address/>
	  <city>Wien</city>
	  <state/>
	  <country>Austria</country>
	  <zip>1090</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Lower back pain localised between 12th rib and gluteal fold
2. Duration of pain of the current period less than seven days
3. Attending the Department of Emergency Medicine at the Vienna General Hospital because of low back pain
4. Agree to be randomised or agree to be included in the patient preference trial
5. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>230</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>230</totalTarget>
      <exclusion>1. History:
1.1. Ingestion of any analgesic drug within 6 hours
1.2. Direct impact trauma
1.3. History of cancer
1.4. Unexplained weight loss (greater than 10 kg within three months)
1.5. Current injection drug use
1.6. Any known chronic infection, such as hepatitis, human immunodeficiency virus (HIV), tuberculosis
1.7. Immunosuppressive therapy (such as systemic corticosteroids, ciclosporine, or such)
1.8. Organ transplantation
1.9. History of inflammatory arthritis of large joints
1.10. Current bowel or bladder dysfunction
1.11. Involved in litigation
1.12. Alcohol abuse
1.13. Aged less than 19 and greater than 65 years
1.14. Current abdominal problems (epigastric pain)
1.15. A history of gastric or duodenal ulcer
1.16. A history of severe renal or hepatic insufficiency or severe coronary insufficiency
1.17. Allergies against any non-steroidal analgesics (NSA) or tizanidin
2. Physical examination:
2.1. Fever greater than 38°C
2.2. Sensory or motor deficit in lower limb
2.3. Lasegue positive greater than 60° 
2.4. Pregnancy: to be ruled out by a commercially available and routinely used urine pregnancy test
2.5. Urinary tact infection: to be ruled out by a commercially available and routinely used urine dip stick test; infection is assumed if nitrite and leukocytes test positive
3. Communication problems:
3.1. Patients who appear not to be able to understand the information provided to give informed consent for participation in this trial because of mental or physical handicaps. It is the duty of the enrolling physician to decide whether a potential participant has sufficient language skills to understand the information provided or to communicate that she/he understands.
3.2. Patients who appear not to be able to understand the information provided to give informed consent for participation in this trial because of language barriers. Those who need an interpreter to communicate with the treating physician are certainly ineligible. Otherwise it is the duty of the enrolling physician to decide whether a potential participant has sufficient language skills to understand the information provided.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Back pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Back pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Stage 1 intervention:
Patients are randomised to oral diclofenac (150 mg) plus intravenous placebo or oral placebo plus intravenous diclofenac (75 mg) in a double blind fashion. The dose of diclofenac for oral administration has to be twice the intravenous dose because of a 50% first pass elimination of the active ingredient. Patients will be assessed after 90 minutes (this is the average time needed for the intravenous administration of an infusion containing analgesics).

The primary endpoint at 90 minutes is pain assessed with a visual analogue scale (VAS), secondary endpoint is the Roland Morris disability questionnaire (RMDQ), and the quality of life score as measured by the 36-item short form health survey (SF-36). If patients still have severe pain further intravenous therapy should be given according to the discretion of the treating physician.

Stage 2 intervention:
After the first step patients are randomised to oral diclofenac (2 x 100 mg/day or 1 x 100 mg/day if bodyweight is less than 60 kg) and the oral muscle-relaxant tizanidin (Sirdalud® 3 x 2 mg, Novartis Pharma AG, Basel, Switzerland) over three days versus oral diclofenac (2 x 100 mg/day or 1 x 100 mg/day if bodyweight is less than 60 kg) plus oral placebo in a double blind fashion. Patients with a history of gastric pain, suggestive of ulcer or non-ulcer dyspeptic disease will receive a proton pump inhibitor for gastric protection (pantoprazol 1 x 40 mg/day, Pantoloc® Byk Pharma Österreich).

Patients who refuse randomisation but agree to participate in the patient preference trial will receive the treatment of their choice (this refers to both stages). Treatment and follow-up will be identical in the randomised and patient preference groups.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Diclofenac, tizanidin (Sirdalud®), pantoprazol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2001 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/11716789 Study protocol</publicationDetails>
      <publicationStage>Protocol</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0774215f-1e3f-48f7-bd70-c2f499d1e332" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2001-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/11716789"/>
	<description>Study protocol</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1252-0</funderId>
      <funderId>Funder1252-1</funderId>
      <funderId>Funder1252-2</funderId>
      <funderId>Funder1252-3</funderId>
      <contactId>Contact5361_1252</contactId>
      <sponsorId>Sponsor5094</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5361_1252">
    <title>Professor</title>
    <forename>Marcus</forename>
    <surname>Müllner</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Universitätsklinik für Notfallmedizin
Allgemeines Krankenhaus der Stadt Wien
Währinger Gürtel 18-20/6/D</address>
      <city>Wien</city>
      <country>Austria</country>
      <zip>1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+43 (1) 40 400 1964</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Marcus.Muellner@univie.ac.at</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5094">
    <organisation>Medical University of Vienna (Austria) </organisation>
    <website>http://www.univie.ac.at/indexengl.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Emergency Medicine
Allgemeines Krankenhaus Wien
Währinger Gürtel 18-20</address>
      <city>Wien</city>
      <country>Austria</country>
      <zip>A-1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.22937.3d</gridId>
    <rorId>https://ror.org/05n3x4p02</rorId>
  </sponsor>
  <funder id="Funder1252-0">
    <name>The Medical-Scientific Fund of the Mayor of Vienna (Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien) (Austria) - protocol submitted for funding, as of 17/10/2001) there is no decision</name>
    <fundRef/>
  </funder>
  <funder id="Funder1252-1">
    <name>Novartis Pharma GmbH (Austria) - covering patient insurance</name>
    <fundRef/>
  </funder>
  <funder id="Funder1252-2">
    <name>Byk Pharma (Austria) - providing pantoprazol</name>
    <fundRef/>
  </funder>
  <funder id="Funder1252-3">
    <name>Novartis Pharma and Byk Pharma will not be involved in data collection, analysis or data interpretation.</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>